Search

Your search keyword '"[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior"' showing total 179 results
Start Over Descriptor "[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior"
179 results on '"[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior"'

1. Anatomical predictors of cognitive decline after subthalamic stimulation in Parkinson’s disease

Author

Bérangère Debilly, Bruno Pereira, Vincent Planche, Dominique Morand, Tiphaine Vidal, Emmanuel de Schlichting, Ingrid de Chazeron, Franck Durif, Pierre-Michel Llorca, Jean-Jacques Lemaire, Fanny Munsch, Philippe Derost, Jerome Coste, Ana Marques, Université de Bordeaux (UB), service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Service de Neurochirurgie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Mémoire de Ressources et de Recherche [CHU Clermont-Ferrand] (CMRR), Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Délégation à la Recherche Clinique et à l'Innovation, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Groupe de sociologie politique et morale (GSPM), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Service de Neurochirurgie [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Université de Bordeaux ( UB ), Centre Hospitalier Universitaire de Clermont-Ferrand, CHU Clermont-Ferrand-Hôpital Gabriel Montpied, Environnement et Grandes Cultures ( EGC ), AgroParisTech-Institut National de la Recherche Agronomique ( INRA ), Institut Pascal - Clermont Auvergne ( IP ), Sigma CLERMONT ( Sigma CLERMONT ) -Université Clermont Auvergne ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Equipe de Recherche en Signal et Imagerie Medicale ( ERIM-ERI 14 ), Université d'Auvergne - Clermont-Ferrand I ( UdA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupe de sociologie politique et morale ( GSPM ), École des hautes études en sciences sociales ( EHESS ) -Centre National de la Recherche Scientifique ( CNRS ), and Centre Mémoire de Ressources et de Recherche [CHU de Clermont-Ferrand]

Subjects
Male, 0301 basic medicine, Parkinson's disease, Neurology, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Deep Brain Stimulation, medicine.medical_treatment, Neuropsychological Tests, Subthalamic nucleus, Nucleus Accumbens, Cohort Studies, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cognition, 0302 clinical medicine, Cognitive decline, ComputingMilieux_MISCELLANEOUS, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, General Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Parkinson Disease, Middle Aged, Magnetic Resonance Imaging, Treatment Outcome, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Cardiology, Female, Anatomy, medicine.symptom, MRI, medicine.medical_specialty, Histology, Deep brain stimulation, Perseveration, Prefrontal Cortex, Nucleus accumbens, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Atrophy, Internal medicine, medicine, Humans, Cognitive Dysfunction, Aged, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Deep-brain stimulation, medicine.disease, 030104 developmental biology, Subthalamus, Parkinson’s disease, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

International audience; We investigated whether pre-operative MRI measures of focal brain atrophy could predict cognitive decline occurring after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson's disease (PD). For that purpose, we prospectively collected data of 42 consecutive patients with PD who underwent bilateral STN-DBS. Normalized brain structure volumes and cortical thicknesses were measured on pre-operative T1-weighted MRI. Patients were tested for their cognitive performances before surgery and 1 year after. After controlling for age, gender, pre-operative disease severity, change in dopaminomimetic dose after surgery and contact location, we found correlations: (1) between the variation of the total Mattis dementia rating scale (MDRS) score and left lateral ventricle volume (p = 0.032), (2) between the variation of the initiation/perseveration subscore of the MDRS and the left nucleus accumbens volume (p = 0.042) and the left lateral ventricle volume (p = 0.017) and (3) between the variation of the backward digit-span task and the right and left superior frontal gyrus thickness (p = 0.004 and p = 0.007, respectively). Left nucleus accumbens atrophy was associated with decline in the initiation/perseveration subscore with the largest effect size (d = − 1.64). Pre-operative left nucleus accumbens volume strongly predicted postoperative decline in the initiation/attention subscore (AUC = 0.92, p < 0.001, 96.3% sensitivity, 80.0% specificity, 92.9% PPV and 92.9% NPV). We conclude that the morphometric measures of brain atrophy usually associated with cognitive impairment in PD can also explain or predict a part of cognitive decline after bilateral STN-DBS. In particular, the left accumbens nucleus volume could be considered as a promising marker for guiding surgical decisions.

Published
2018

2. Decision-making under risk of gain in young children and mangabey monkeys

Author

Elisa Augustin, Catherine Blois-Heulin, James Rivière, Mathilde Stomp, Alban Lemasson, Psychologie et Neurosciences de la Cognition et de l'affectivité (PSY-NCA), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Ethologie animale et humaine (EthoS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), GIS ‘Game and Society’, incentive action fromRennes 1 University, Psychologie et Neurosciences de la Cognition et de l'affectivité ( PSY-NCA ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Ethologie animale et humaine ( EthoS ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Université de Caen Normandie ( UNICAEN ), Centre de Recherche sur les Fonctionnement et les Dysfonctionnements Psychologiques (CRFDP), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Cercocebus, primates, Decision Making, Child Behavior, 050105 experimental psychology, Developmental psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 03 medical and health sciences, Behavioral Neuroscience, Risk-Taking, 0302 clinical medicine, Developmental Neuroscience, [SDV.BA.ZV]Life Sciences [q-bio]/Animal biology/Vertebrate Zoology, Inhibitory control, Developmental and Educational Psychology, Animals, Humans, 0501 psychology and cognitive sciences, Mangabey, risk, Cercocebus torquatus, Behavior, Animal, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, biology, [SCCO.NEUR]Cognitive science/Neuroscience, 05 social sciences, economic choice, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, biology.organism_classification, Preference, gambling, Child, Preschool, [ SCCO.NEUR ] Cognitive science/Neuroscience, [ SDV.BA.ZV ] Life Sciences [q-bio]/Animal biology/Vertebrate Zoology, Female, Psychology, Psychomotor Performance, 030217 neurology & neurosurgery, Developmental Biology
Abstract

International audience; In contrast to human adults, risk proneness in the gain domain is usually observed in both young children and non-human primates. It is currently unclear what mechanism might be underlying such economic preferences. We investigated decision-making under risk of gain in toddlers and monkeys. The choices of 2.5-year-old children and red-capped mangabeys (Cercocebus torquatus torquatus) were examined in a gambling task for food reward in which participants have to choose between two options, a secure option and a risky option. In contrast to monkeys, toddlers showed a strong preference for the risky option over the safe option. In order to test the hypothesis that risky choices in participants reflect inhibitory control difficulties, toddlers and mangabeys were presented in Experiment 2 with a situation analogous to that used in Experiment 1 except for the fact that the opaque cover under which was placed the secure option was replaced by a transparent cover. In this second experiment, toddlers continued to show a preference for the risky option over the safe option. In contrast, mangabeys showed a preference for the safe option over the risky option in Trial 1 but they shifted their economic preferences in Trial 2. We argue that decision-making strategies under risk of gain in both toddlers and mangabeys (a) do not reflect poor behavioral control and (b) are not reducible to perception-action couplings.

Published
2017

3. Food addiction: Definition, measurement and limits of the concept, associated factors, therapeutic and clinical implications

Author

Paul Brunault, Sarah Cathelain, Christian Réveillère, Nicolas Ballon, Robert Courtois, Psychologie des âges de la vie et adaptation (PAVeA), Université de Tours, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Psychologie des âges de la vie ( PAVeA ), Equipe de Liaison et de Soins en Addictologie, CHRU Tours, Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ), Université de Tours (UT), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
0301 basic medicine, Food addiction, [ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, troubles liés à l'usage de substance, substance related and addictive disorders, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 03 medical and health sciences, modèle biopsychosocial, biopsychosocial model, mental disorders, addictive disorders, Medicine, troubles addictifs, ComputingMilieux_MISCELLANEOUS, 030109 nutrition & dietetics, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, food addiction, addiction à l'alimentation, General Medicine, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, 16. Peace & justice, 3. Good health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SCCO.PSYC]Cognitive science/Psychology, [ SCCO.NEUR ] Cognitive science/Neuroscience, addiction, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Humanities
Abstract

International audience; •Addictions, which are characterized by the inability to control a behavior despite existence of physical or psychological consequences, have biological, psychological and social determinants.•Although the possibility of developing an addiction to some psychoactive substances (e.g. alcohol, tobacco, cannabis) and to gambling (i.e., gambling disorder) is now well-demonstrated, the possibility to develop a non-drug addiction (i.e., behavioral addiction) to certain behaviors which provide pleasure (e.g. eating, having sex, buying things) is still in debate.•The concept of food addiction, which refers to people who exhibit substance dependence criteria in relation to some high-fat and high-sugar foods, was recently proposed by applying substance dependence DSM criteria to eating behavior.•To assess food addiction, the Yale Food Addiction Scale is now the only self-administered questionnaire (diagnosis and estimate of the number of symptoms of food addiction).•Prevalence for food addiction is higher in overweight and obese patients, and in patients with certain psychopathological characteristics (i.e., depression, Attention Deficit Hyperactivity Disorder, high impulsivity), in patients who are single and in patients with neurobiological alterations in the reward system. However, it is still unclear whether food addiction is necessary associated with subsequent increase in body weight and/or obesity.•An increasing number of studies demonstrated that drug addiction and food addiction shares some similar clinical, neurobiological and psychopathological and sociocultural risk factors. To test the pertinence to include food addiction as an addiction, it would be interesting to conduct future studies in patients who may experience harms related to their food addiction, including not only patients with obesity, but also patients with metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia, atherosclerosis, stroke, or coronary heart disease.•Food addiction is a clinical and multidimensional concept which requires integrated care with psychotherapy, pharmacological and social lines of approach. This concept has also practical implications in terms of prevention and public health (e.g., prevention, brief interventions, possible law enforcement regarding some kinds of food which could present some addictive properties).; •Les addictions, qui se caractérisent par une impossibilité à contrôler un comportement malgré la connaissance de ses conséquences négatives, ont des déterminants biologiques, psychologiques et sociaux.•S’il est désormais bien démontré qu’il est possible de développer une addiction vis-à-vis de certaines substances psychoactives (i.e., alcool, tabac, cannabis) et de la pratique des jeux de hasard et d’argent (i.e., jeu pathologique) la possibilité de développer une addiction sans drogue (ou addiction comportementale) vis-à-vis d’autres comportements sources de plaisir (i.e., alimentation, conduites sexuelles, achats) est encore débattue. •Le concept d’addiction à l’alimentation, qui fait référence à une relation de dépendance d’un individu vis-à-vis de certains aliments riches en graisse ou en sucre, a été récemment proposé en appliquant au comportement alimentaire les critères DSM de dépendance à une substance.•Pour mesurer l’addiction à l’alimentation, la Yale Food Addiction Scale est actuellement l’auto-questionnaire de référence (diagnostic d’addiction à l’alimentation et évaluation du nombre de symptômes d’addiction à l’alimentation). •L’addiction à l’alimentation est plus fréquente chez les patients obèses, chez les patients présentant certaines caractéristiques psychopathologiques (dépression, trouble déficitaire de l’attention avec ou sans hyperactivité, forte impulsivité), célibataires ou encore, qui présentent certaines altérations neurobiologiques du système de la récompense. Il n’est par contre pas démontré à l’heure actuelle que ce trouble soit systématiquement responsable d’une prise de poids et/ou d’une obésité. •Un nombre croissant de travaux soulignent les proximités cliniques, neurobiologiques et en termes de facteurs de risque (biologiques, psychopathologiques, socio-culturels) entre l’addiction à l’alimentation et les autres addictions. Afin de tester la pertinence de considérer l’addiction à l’alimentation comme une addiction à part entière, il serait intéressant de réaliser des études auprès de patients pouvant présenter d’autres dommages que l’obésité : patients souffrant de syndrome métabolique, diabète de type 2, hypertension, dyslipidémie, athérosclérose, accident vasculaire cérébral ou cardiopathie ischémique.•L’addiction à l’alimentation est un concept clinique multidimensionnel qui requiert une prise en charge intégrative impliquant des axes psychothérapeutiques, pharmacologiques et sociaux. L’intérêt de ce concept réside également dans ses implications en termes de prévention et de santé publique, via par exemple la possibilité de mesures de prévention précoces ciblées sur les patients vulnérables (information et interventions précoces, voire réglementation).

Published
2016

4. Data in support of the identification of neuronal and astrocyte proteins interacting with extracellularly applied oligomeric and fibrillar α-synuclein assemblies by mass spectrometry

Author

Virginie Redeker, Luc Bousset, Ronald Melki, Antoine Triller, Thomas Liebmann, Amulya Nidhi Shrivastava, Laura Pieri, Leandro G. Almeida, Maria Spolidoro, Anita Aperia, Marianne Renner, Clément Léna, Nicolas Fritz, Institut de biologie de l'Ecole Normale Supérieure ( IBENS ), École normale supérieure - Paris ( ENS Paris ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Department of Women's and Children's Health, Karolinska University Hospital [Stockholm], Institut de biologie de l'ENS Paris (UMR 8197/1024) (IBENS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Biologie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie de l'ENS Paris (IBENS), and Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de Biologie - ENS Paris

Subjects
0301 basic medicine, Lysis, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Cell, Shotgun, Pull down, Biology, lcsh:Computer applications to medicine. Medical informatics, Mass spectrometry, Bioinformatics, Proteomic Analysis, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 03 medical and health sciences, medicine, Database search engine, lcsh:Science (General), ComputingMilieux_MISCELLANEOUS, Data Article, Multidisciplinary, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Alpha-synuclein assemblies, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cell biology, 030104 developmental biology, medicine.anatomical_structure, nervous system, Parkinson׳s disease, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, lcsh:R858-859.7, α synuclein, lcsh:Q1-390, Astrocyte
Abstract

α-Synuclein (α-syn) is the principal component of Lewy bodies, the pathophysiological hallmark of individuals affected by Parkinson disease (PD). This neuropathologic form of α-syn contributes to PD progression and propagation of α-syn assemblies between neurons. The data we present here support the proteomic analysis used to identify neuronal proteins that specifically interact with extracellularly applied oligomeric or fibrillar α-syn assemblies (conditions 1 and 2, respectively) (doi: 10.15252/embj.201591397 [1]). α-syn assemblies and their cellular partner proteins were pulled down from neuronal cell lysed shortly after exposure to exogenous α-syn assemblies and the associated proteins were identified by mass spectrometry using a shotgun proteomic-based approach. We also performed experiments on pure cultures of astrocytes to identify astrocyte-specific proteins interacting with oligomeric or fibrillar α-syn (conditions 3 and 4, respectively). For each condition, proteins interacting selectively with α-syn assemblies were identified by comparison to proteins pulled-down from untreated cells used as controls. The mass spectrometry data, the database search and the peak lists have been deposited to the ProteomeXchange Consortium database via the PRIDE partner repository with the dataset identifiers PRIDE: http://www.ebi.ac.uk/pride/archive/projects/PXD002256 to PRIDE: http://www.ebi.ac.uk/pride/archive/projects/PXD002263 and doi: 10.6019/http://www.ebi.ac.uk/pride/archive/projects/PXD002256 to 10.6019/http://www.ebi.ac.uk/pride/archive/projects/PXD002263. Keywords: Parkinson׳s disease, Alpha-synuclein assemblies, Proteomic Analysis, Pull down

Published
2016

5. Gambling behaviors and psychopathology related to Attention-Deficit/Hyperactivity Disorder (ADHD) in problem and non-problem adult gamblers

Author

Mélina Fatséas, Jean-Marc Alexandre, Lucia Romo, Groupe Jeu, Alice Guilleux, Amandine Luquiens, Jean-Luc Venisse, David Magalon, Marie Grall-Bronnec, Isabelle Chéreau-Boudet, Marc Valleur, Gaëlle Challet-Bouju, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Santé mentale et santé publique (SMSP - U1178), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Santé mentale et santé publique ( SMSP - U1178 ), Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Centre Hospitalier Universitaire de Nantes

Subjects
Male, Attention Deficit Hyperactivity Disorder, [SHS.PSY]Humanities and Social Sciences/Psychology, 030508 substance abuse, [ SCCO.PSYC ] Cognitive science/Psychology, Comorbidity, Problem gambling, Cohort Studies, 0302 clinical medicine, Personality traits, media_common, Pathological gambling, Psychopathology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Middle Aged, 3. Good health, Psychiatry and Mental health, [SCCO.PSYC]Cognitive science/Psychology, Female, 0305 other medical science, Psychology, Personality, Clinical psychology, Adult, medicine.medical_specialty, media_common.quotation_subject, Addiction, Dysfunctional family, Psychiatric Comorbidity, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, Young Adult, 03 medical and health sciences, mental disorders, medicine, Humans, Attention deficit hyperactivity disorder, Psychiatry, Biological Psychiatry, Mini-international neuropsychiatric interview, medicine.disease, 030227 psychiatry, Behavior, Addictive, Attention Deficit Disorder with Hyperactivity, Gambling, Temperament and Character Inventory
Abstract

International audience; Previous studies showed that Pathological Gambling and Attention Deficit/Hyperactivity Disorder (ADHD) often co-occur. The aim of this study was to examine whether ADHD is associated with specific severity patterns in terms of gambling behavior, psychopathology and personality traits. 599 problem and non-problem-gamblers were recruited in addiction clinics and gambling places in France. Subjects were assessed with the Wender-Utah Rating Scale-Child, the Adult ADHD Self-Report Scale, the Mini International Neuropsychiatric Interview, the Temperament and Character Inventory, the South Oaks Gambling Screen and questionnaires assessing gambling related cognitive distortions and gambling habits. 20.7% (n=124) of gamblers were screened positive for lifetime or current ADHD. Results from the multivariate analysis showed that ADHD was associated with a higher severity of gambling-related problems and with more psychiatric comorbidity. Among problem gamblers, subjects with history of ADHD were also at higher risk for unemployment, psychiatric comorbidity and specific dysfunctional personality traits. This study supports the link between gambling related problems and ADHD in a large sample of problem and non-problem gamblers, including problem-gamblers not seeking treatment. This points out the necessity to consider this disorder in the prevention and in the treatment of pathological gambling.

Published
2016

6. High prevalence of psychiatric disorders in patients with skin-restricted lupus: a case-control study

Author

I, Jalenques, F, Rondepierre, C, Massoubre, E, Haffen, J P, Grand, B, Labeille, J L, Perrot, F, Aubin, F, Skowron, A, Mulliez, M, D'Incan, J, Waton, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), University Hospital of St-Etienne, Department of Dermatology, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC ( NEURO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Universitaire de Saint-Etienne ( CHU de Saint-Etienne ), Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Service de Dermatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)

Subjects
Adult, Male, Mental Health Services, medicine.medical_specialty, Generalized anxiety disorder, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Suicide, Attempted, Dermatology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Lupus Erythematosus, Cutaneous, Prevalence, medicine, Humans, Psychiatry, ComputingMilieux_MISCELLANEOUS, Depression (differential diagnoses), Mini-international neuropsychiatric interview, Lupus erythematosus, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Mental Disorders, [SCCO.NEUR]Cognitive science/Neuroscience, Panic disorder, Alcohol dependence, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Middle Aged, medicine.disease, 030227 psychiatry, 3. Good health, Socioeconomic Factors, Case-Control Studies, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Major depressive disorder, Anxiety, Female, France, medicine.symptom, business
Abstract

BACKGROUND Psychiatric disorders have been extensively documented in patients with systemic lupus erythematosus (SLE). However, the prevalence of psychiatric disorders in patients with skin-restricted lupus (SRL) remains unknown, although SRL is more common than SLE. OBJECTIVES To assess current and lifetime prevalence of Axis I psychiatric disorders among outpatients with SRL and to examine the factors associated with psychiatric disorders among such patients. METHODS A multicentre case-control study involving outpatients with SRL and controls matched for sex, age and education level. The Mini International Neuropsychiatric Interview was used for psychiatric evaluation. RESULTS We evaluated 75 patients and 150 controls. Of these, 49% of patients vs. 13% of controls fulfilled the criteria for at least one current psychiatric disorder (P < 0·001). The following disorders were significantly more frequent among patients than controls: current and lifetime major depressive disorder (9% vs. 0%, P < 0·001 and 44% vs. 26%, P = 0·01), generalized anxiety disorder (23% vs. 3%, P < 0·001 and 35% vs. 19%, P = 0·03), panic disorder (7% vs. 0%, P = 0·004 and 21% vs. 3%, P < 0·001), current suicide risk (24% vs. 7%, P = 0·003), alcohol dependence (7% vs. 0%, P = 0·004) and lifetime agoraphobia (20% vs. 9%, P = 0·01). Lupus duration and lupus past treatment by thalidomide were significantly higher among patients with current psychiatric disorders. CONCLUSIONS This study demonstrates a high prevalence of several psychiatric disorders (anxiety, depression, suicide risk, alcohol dependence) in patients with SRL.

Published
2016

7. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study

Author

W. Wolfgang Fleischhacker, Julio Bobes, Anna-Greta Nylander, Nicholas Moore, Maxine X. Patel, Christophe Sapin, Nawal Bent-Ennakhil, Jean-Yves Loze, Pierre-Michel Llorca, Stephan Heres, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Department of Psychiatry, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)-University of Oviedo, INSERM U657, CIC-P0005, Département de pharmacologie, Université Bordeaux Segalen - Bordeaux 2, Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM)-University of Oviedo, Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)

Subjects
Male, Antipsychotic agents, viruses, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Quality of life, immune system diseases, Longitudinal Studies, ComputingMilieux_MISCELLANEOUS, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Long-acting injectable, virus diseases, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Middle Aged, 3. Good health, ddc, Europe, Psychiatry and Mental health, Prescriptions, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, Schizophrenic Psychology, medicine.drug, Antipsychotic Agents, Adult, medicine.medical_specialty, Injections, Intramuscular, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Disease severity, medicine, Humans, Paliperidone, Medical prescription, Psychiatry, Antipsychotic, Medication adherence, Psychiatric Status Rating Scales, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, 030227 psychiatry, Long acting, Delayed-Action Preparations, Non interventional, Quality of Life, business, 030217 neurology & neurosurgery
Abstract

Background:The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-interventional study across several European countries examining prescription of long-acting injectable (LAI) antipsychotics to identify sociodemographic and clinical characteristics of patients receiving and physicians prescribing LAIs. ALTO was also the first large-scale study in Europe to report on the use of both first- or second-generation antipsychotic (FGA- or SGA-) LAIs.Methods:Patients with schizophrenia receiving a FGA- or SGA-LAI were enrolled between June 2013 and July 2014 and categorized as incident or prevalent users. Assessments included measures of disease severity, functioning, insight, well-being, attitudes towards antipsychotics, and quality of life.Results:For the 572 patients, disease severity was generally mild-to-moderate and the majority were unemployed and/or socially withdrawn. 331/572 were prevalent LAI antipsychotic users; of whom 209 were prescribed FGA-LAI. Paliperidone was the most commonly prescribed SGA-LAI (56% of incident users, 21% of prevalent users). 337/572 (58.9%) were considered at risk of non-adherence. Prevalent LAI users had a tendency towards better insight levels (PANSS G12 item). Incident FGA-LAI users had more severe disease, poorer global functioning, lower quality of life, higher rates of non-adherence, and were more likely to have physician-reported lack of insight.Conclusions:These results indicate a lower pattern of FGA-LAI usage, reserved by prescribers for seemingly more difficult-to-treat patients and those least likely to adhere to oral medication.

Published
2018

8. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort

Author

Laurent Boyer, Franck Schürhoff, Christophe Lançon, A. Schandrin, Bruno Aouizerate, C. Passerieux, Thierry d'Amato, Delphine Capdevielle, Marion Leboyer, Julien Dubreucq, M. Andrianarisoa, N Coulon, Fabrice Berna, Guillaume Fond, Jasmina Mallet, Lore Brunel, Romain Rey, Ophélia Godin, Caroline Dubertret, Pierre-Michel Llorca, Pierre Vidailhet, Isabelle Chereau, David Misdrahi, Sylvain Leignier, Catherine Faget, E. Bulzacka, Mathieu Urbach, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurosciences sensorielles et cognitives (NSC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Université Pierre et Marie Curie - Paris 6 (UPMC), Fondation FondaMental [Créteil], Hôpital Charles Perrens, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de psychiatrie, CHU Clermont-Ferrand, Psychopathologie et neurobiologie de la schizophrénie et de la vulnérabilité à la psychose, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service de Psychiatrie D Adultes, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Neuropsychologie Cognitive et Prise en Charge des Troubles de la Communication Schizophreniques, Institut National de la Santé et de la Recherche Médicale (INSERM), FondaMental Foundation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Albert Chenevier-Fondation de Coopération Scientifique, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre hospitalier Charles Perrens [Bordeaux], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants ( SPMC ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Aix Marseille Université ( AMU ), Fédération de Médecine Translationnelle de Strasbourg ( FMTS ), Université de Strasbourg ( UNISTRA ), Universite ́ Pierre et Marie Curie-Paris, F-75005, Paris, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Institut d'Electronique et de Télécommunications de Rennes ( IETR ), Université de Nantes ( UN ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National des Sciences Appliquées - Rennes ( INSA Rennes ) -CentraleSupélec-Centre National de la Recherche Scientifique ( CNRS ), Université Claude Bernard Lyon 1 ( UCBL ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hôpital Sainte-Marguerite [CHU - APHM] ( Hôpitaux Sud ), Neuropsychologie Cognitive et prise en Charge des Troubles de la Communication schizophréniques, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Albert Chenevier-Fondation de Coopération Scientifique, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), and CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA )

Subjects
Male, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Comorbidity, Cohort Studies, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Prevalence, ComputingMilieux_MISCELLANEOUS, Depression (differential diagnoses), [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Remission Induction, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Antidepressive Agents, 3. Good health, Psychiatry and Mental health, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Major depressive disorder, Antidepressant, Female, France, medicine.symptom, Adult, medicine.medical_specialty, behavioral disciplines and activities, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Young Adult, 03 medical and health sciences, Delusion, Internal medicine, mental disorders, medicine, Humans, Antipsychotic, Avolition, Psychiatric Status Rating Scales, Depressive Disorder, Major, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Odds ratio, medicine.disease, 030227 psychiatry, Logistic Models, Multivariate Analysis, Quality of Life, business, 030217 neurology & neurosurgery
Abstract

BackgroundMajor depressive disorder (MDD) is underdiagnosed and undertreated in schizophrenia, and has been strongly associated with impaired quality of life.AimsTo determine the prevalence and associated factors of MDD and unremitted MDD in schizophrenia, to compare treated and non-treated MDD.MethodParticipants were included in the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment. MDD was defined by a Calgary score ≥6. Non-remitted MDD was defined by current antidepressant treatment (unchanged for >8 weeks) and current Calgary score ≥6.Results613 patients were included and 175 (28.5%) were identified with current MDD. MDD has been significantly associated with respectively paranoid delusion (odds ratio 1.8; P = 0.01), avolition (odds ratio 1.8; P = 0.02), blunted affect (odds ratio 1.7; P = 0.04) and benzodiazepine consumption (odds ratio 1.8; P = 0.02). Antidepressants were associated with lower depressive symptoms score (5.4 v. 9.5; P < 0.0001); however, 44.1% of treated patients remained in non-remittance MDD. Nonremitters were found to have more paranoid delusion (odds ratio 2.3; P = 0.009) and more current alcohol misuse disorder (odds ratio 4.8; P = 0.04). No antidepressant class or specific antipsychotic were associated with higher or lower response to antidepressant treatment. MDD was associated with Metabolic syndrome (31.4 v. 20.2%; P = 0.006) but not with increased C-reactive protein.ConclusionsAntidepressant administration is associated with lower depressive symptom level in patients with schizophrenia and MDD. Paranoid delusions and alcohol misuse disorder should be specifically explored and treated in cases of non-remission under treatment. MetS may play a role in MDD onset and/or maintenance in patients with schizophrenia.Declaration of interestNone.

Published
2018

9. Le Big Five Inventory français permet-il d’évaluer des facettes en plus des cinq grands facteurs ?

Author

Robert Courtois, Jean-Michel Petot, Gilles Lecocq, Baptiste Lignier, Odile Plaisant, Département de Psychologie, Université de Tours, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Laboratoire de psychopathologie et psychologie médicale ( LPPM ), Université de Bourgogne ( UB ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Laboratoire de psychopathologie et psychologie médicale (LPPM), and Université de Bourgogne (UB)

Subjects
Agreeableness, Facettes, International Personality Item Pool, ésBFI, Cinq grandes dimensions de personnalité, [SHS.PSY]Humanities and Social Sciences/Psychology, 050109 social psychology, Hostility, [ SCCO.PSYC ] Cognitive science/Psychology, Facets, Aspects, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 0302 clinical medicine, Arts and Humanities (miscellaneous), Openness to experience, medicine, 0501 psychology and cognitive sciences, ComputingMilieux_MISCELLANEOUS, Extraversion and introversion, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 05 social sciences, Conscientiousness, 16. Peace & justice, 030227 psychiatry, Psychiatry and Mental health, Facet (psychology), [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SCCO.PSYC]Cognitive science/Psychology, Five factor model, medicine.symptom, Personality Assessment Inventory, Psychology, Humanities, NEO PI-R, Personality
Abstract

International audience; RésuméIntroduction Le Big Five Inventory (BFI) de John (1991) représente un des outils les plus consensuels de l'évaluation dimensionnelle de la personnalité. Les cinq grandes dimensions qu'il mesure sont~: l'Extraversion, l'Agréabilité, le Caractère consciencieux, le Névrosisme et l'Ouverture. Soto et John (2009) ont montré qu'il était possible de considérer deux facettes par dimension du BFI. L'objectif de cette étude est de savoir s'il est possible de retrouver ces dix facettes dans un échantillon français, en s'appuyant sur les corrélations avec les facettes équivalentes du NEO PI-R (NEO Personality Inventory Revised). Méthode Le premier échantillon constitué de 360~étudiants de l'Institut libre d'éducation physique supérieure (ILEPS) et de l'Université de Tours (en psychologie) a permis de tester la validité externe des facettes du BFI-Fr en lien avec celles du NEO PI-R. Le second échantillon constitué de 142~étudiants de psychologie de l'Université de Tours a permis de rechercher la validité temporelle (test et retest). Le troisième échantillon constitué de 252~étudiants en psychologie de l'Université de Paris-Nanterre a permis de tester la forme hétéro-évaluative du BFI-Fr. Résultats et discussion Le BFI-Fr permet d'évaluer neuf des dix facettes proposées par Soto et John~: Activité et Assertivité pour la dimension Extraversion~; Altruisme et Compliance pour la dimension Agréabilité~; Ordre et Autodiscipline pour la dimension Caractère consciencieux~; Anxiété pour la dimension Névrosisme~; Ouverture à l'esthétique et Ouverture aux idées pour la dimension Ouverture. L'étude a permis de définir une facette Instabilité émotionnelle en remplacement de la facette Dépression du Névrosisme qui ne présentait pas de qualités psychométriques suffisantes. AbstractIntroduction The Big Five Inventory (BFI) developed by John et al. (1991) is one of the most widely accepted tools for assessing dimensions of personality. It comprises 44 items that assess five broad dimensions of personality (the Big Five Factors): Extraversion, Agreeableness, Conscientiousness, Neuroticism and Openness to experience. Based on correlations with the facets described in the NEO Personality Inventory Revised (NEO PI-R), another Big Five assessment tool with 240 items and 6 facets per dimension, Soto and John (2009) showed that the dimensions in the BFI could be divided into two facets each (ten facets altogether). These results are in line with those of DeYoung et al. (2007), who ran factorial analyses with all the NEO PI-R facets and the International Personality Item Pool (IPIP) and identified ten intermediate factors (between facets and dimensions) which they called ``aspects'' (two per dimension). The goal of the present study is to investigate the ten facets described by Soto and John in a French sample, using the French version of the BFI (BFI-Fr), which has good psychometric properties, and to check whether the pattern of correlations of these facets with the NEO PI-R match those of the American version. Method We created three groups. The first comprised 360 students from the Institut libre d'éducation physique supérieure (ILEPS) and Tours University (psychology undergraduates). Participants (mean age 21.1 years ± 2.30; 58% women) completed the BFI-Fr and the NEO PI-R. The second comprised 142 psychology students from Tours University (mean age 20.6 years ± 1.78; 81% women); they completed the BFI-Fr twice, two weeks apart (test and retest). The third comprised 252 psychology students from Paris-Nanterre University (mean age 23 years ± 4.2; 89% women) who described a total of 405 people they knew well (mean age 35.2 ± 10.8; 49% women) using the peer-report format of the BFI-Fr. Results In the self-report format, eight of Soto and John's ten aspects had acceptable internal consistency (based on Guildford's (1954) internal consistency criteria, due to the small number of items), with Cronbach's α between 0.60 and 0.86 and test-retest correlations between 0.71 and 0.89, showing satisfactory temporal stability. We found a single facet for Extraversion (Assertiveness), two for Agreeableness (Altruism and Compliance), two for Conscientiousness (Self-Discipline and Order), one for Neuroticism (Anxiety), and two for Openness to Experience (Openness to aesthetics and Openness to ideas). Based on their convergence with the corresponding facets in the NEO PI-R, these eight facets showed satisfactory external validity. With regard to the peer-report format, the Activity facet of Extraversion, which did not have sufficient internal consistency in the self-report format, had acceptable properties (i.e. 9 out of 10 facets). Only the Depression facet of Neuroticism still had insufficient internal consistency. In this study, we proposed an improvement of two facets (Activity and Compliance) and added one facet specific to the French version (Emotional Instability) in place of the Depression facet. Discussion We showed that the BFI-Fr can be used to assess nine of the ten facets described by Soto and John. We also identified an Emotional Instability facet, replacing the Depression facet of Neuroticism. DeYoung et al. (2007) considered that anxiety and depression are indissociable and can be represented by a Neuroticism aspect they labeled Withdrawal. They suggested a second aspect of this dimension they called Volatility (with the N2 Angry Hostility facet of the NEO PI-R as main marker and the N5 Impulsiveness and N3 Depression as secondary markers). The Emotional Instability facet we found corresponds closely to the N2 Angry Hostility facet of the NEO PI-R and appears to be a satisfactory marker of DeYoung et al.'s (2007) Volatility aspect. Although this study has limitations, particularly related to the samples (students), the BFI-Fr facets (derived from those defined by Soto and John in the BFI or proposed as improvements on the original facets) match the corresponding NEO PI-R facets and can also be seen as main markers of the aspects defined by DeYoung et al.

Published
2018

10. Relevance of treated cocaine users’ retrospective memory of first cocaine use

Author

Jean Pierre Lepine, Frank Bellivier, Philippe Faure, Emily Karsinti, Georges Brousse, Uwe Maskos, El Hedi Zerdazi, Kristel Piani, Florence Vorspan, Lucia Romo, Vanessa Bloch, Département de Psychiatrie et de Médecine Addictologique, GH Saint-Louis - Lariboisière, Paris, Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Neurobiologie intégrative des Systèmes cholinergiques, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Neuroscience Paris Seine (NPS), Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Université Paris Diderot - Paris 7 (UPD7), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), This study was supported by the French Ministry of Health (PHRC National Programme Hospitalier de Recherche Clinique) (AOM10165). This work was also supported by the Investissement d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02. The groups of FB, UM, PF are members of the Bio-Psy Labex and supported by this program. The funding sponsors had no involvment in study design, collection, analysis, or interpretation of data, writing the manuscript, and the decision to submit the manuscript for publication., ANR-11-IDEX-0004-02/11-LABX-0035,BIOPSY,Laboratoire de Psychiatrie Biologique(2011), Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), ALPOL Cosmétique, Alpol Cosmétique, Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Centre de Biochimie Structurale [Montpellier] ( CBS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Neuropsychopharmacologie des addictions. Vulnérabilité et variabilité expérimentale et clinique ( NAVVEC (UM 81) ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut des sciences du Médicament -Toxicologie - Chimie - Environnement ( IFR71 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Neurobiologie intégrative des Systèmes cholinergiques (NISC), Neurosciences Paris Seine (NPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Biologie Paris Seine (IBPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)

Subjects
Male, Time Factors, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Cocaine, Retrospective memory, Surveys and Questionnaires, ComputingMilieux_MISCELLANEOUS, Outcome, Principal Component Analysis, biology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Middle Aged, 3. Good health, Psychiatry and Mental health, Inhibition, Psychological, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, First use, [ SCCO.NEUR ] Cognitive science/Neuroscience, Anxiety, Female, medicine.symptom, Opiate, Clinical psychology, Adult, medicine.drug_class, Memory, Episodic, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Cocaine-Related Disorders, Sex Factors, Memory, medicine, Tachypsychia, Humans, Biological Psychiatry, Retrospective Studies, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, biology.organism_classification, 030227 psychiatry, Disinhibition, Sedative, Subjective effects, Time Perception, Cocaine use, Cannabis, business, 030217 neurology & neurosurgery
Abstract

International audience; Little is known regarding between-subject variability in the subjective effects of first cocaine use. This study retrospectively assesses the subjective effects of first cocaine use in 160 current treatment-seeking cocaine use disorder patients. Subjective effects of first cocaine use were evaluated with an ad-hoc questionnaire used for cannabis effects. A principal component analysis (PCA) was performed, with resulting factors correlated with clinical variables (α = 0.05). Four factors emerged in the PCA, namely Anxiety (accounting for 21.5% of questionnaire variance), Disinhibition (17.3%), Tachypsychia (16%) and Calmness (13%). Male gender was associated with Disinhibition and Tachypsychia. Cocaine severity factors were associated with Disinhibition, Tachypsychia and Calmness. Opiate, sedative and poppers uses were associated with Anxiety, Tachypsychia and Calmness. The retrospective assessment of the subjective effects of first cocaine use shows significant variability. The different dimensions of subjective first effects are influenced by age, gender and previous substance use history, as well as characteristics of first cocaine use and cocaine-related outcomes.

Published
2018

11. Agile robotic fliers: a morphing based approach

Author

Riviere, Valentin, Manecy, Augustin, Viollet, Stéphane, ONERA - The French Aerospace Lab ( Toulouse ), ONERA, Institut des Sciences du Mouvement Etienne Jules Marey ( ISM ), Centre National de la Recherche Scientifique ( CNRS ) -Aix Marseille Université ( AMU ), Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), ONERA / DTIS, Université de Toulouse [Toulouse], ONERA-PRES Université de Toulouse, and Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Computer Science::Robotics, quadrotors, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, obstacle avoidance, aerial robot, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, elastic folding mechanism, [ SPI.AUTO ] Engineering Sciences [physics]/Automatic, morphing robot, bioinspired, Original Articles, ComputingMethodologies_COMPUTERGRAPHICS, [SPI.AUTO]Engineering Sciences [physics]/Automatic
Abstract

International audience; The aerial robot presented here for the rst time was based on a quadrotor structure, which is capable of unique morphing performances based on an actuated elastic mechanism. Like birds, which are able to negotiate narrow apertures despite their relatively large wingspan, our Quad-Morphing robot was able to pass through a narrow gap at a high forward speed of 2.5m.s −1 by swiftly folding up the structure supporting its propellers. A control strategy was developed to deal with the loss of controllability on the roll axis resulting from the folding process, while keeping the robot stable until it has crossed the gap. In addition, a complete recovery procedure was also implemented to stabilize the robot after the unfolding process. A new metric was also used to quantify the gain in terms of the gap crossing ability in comparison with that observed with classical quadrotors with rigid bodies. The performances of these morphing robots are presented, and experiments performed with a real ying robot passing through a small aperture by reducing its wingspan by 48% are described and discussed. 1 Objective Flying through cluttered environments requires an outstanding level of agility, which often involves the ability to trigger aggressive maneuvers to quickly avoid obstacles or pass through gaps at high speed. In the living world, agility is not restricted to ying insects or even small birds such as hummingbirds. Larger birds such as goshawks [1] and budgerigars [2] are able to negotiate cluttered environments at high speed despite their relatively large wingspan. How do they manage to perform tasks of this kind? By morphing their shape dynamically and reducing their wingspan swiftly by tucking up their wings. Morphing abilities give a ying robot agility by momentarily reducing its wingspan while keeping a suciently high payload. Morphing does not require any aggressive maneuvers but fast embedded mechanisms for folding up the robot's structure, as described in [3] for a winged drone. In the eld of robotics, Unmanned Aerial Vehicles (UAVs) are being used increasingly in cluttered and indoor environments for various purposes such as search and rescue expeditions [4], mapping [5] and exploration [6]. The latest ying robots therefore have to be able to avoid collisions and handle narrow gaps successfully. Quadrotors, with their hovering and Vertical Take-O and Landing (VTOL) abilities, are certainly among the best candidates for meeting these requirements. Here we focused on designing a narrow gap-crossing strategy which was implemented on a quadro-tor. One previous strategy, which has been widely studied consisted in performing aggressive maneuvers to make the quadrotor change its attitude swiftly in order to pass through a vertical or tilted window [7]. Recent studies [8, 9] have succeeded in developing autonomous robotic gap crossing skills based on on-board sensing and computing processes. However, this aggressive attitude control approach has several limitations: the robots have to reach high velocities and angular accelerations which require low inertia of the robot's body as well as high sensor refresh rates, especially in the case of visual sensors so as to prevent blur motion and maintain accurate position estimation with respect to the gap to be crossed. To address this issue, a new approach was adopted based on morphological changes. Previous authors have presented various types of quadrotors in which the size of the structure can be adapted either passively or dynamically for dierent purposes. Non-actuated structures were used by [10] to ensure resilience to collision and by [11] to obtain a self-deployable system facilitating the robot's transport. Actuated structures were used by [12] to reduce the wingspan of a hovering robot or to reduce the robot's volume with a scissor-like foldable structure in [13]. Simulated robotic platforms with morphing abilities have been endowed by [14] with full attitude control and by [15] with an interesting tilting rotor mechanism.

Published
2018

12. The conscious experience in psychotherapies (II): Epistemological reflections on the hypnotic phenomenon.Jean Vion-Dury * et Gaëlle Mougin**($)

Author

Vion-Dury , Jean, Mougin , Gaëlle, Perception, Représentations, Image, Son, Musique ( PRISM ), Aix Marseille Université ( AMU ) -Ecole supérieure d'Art d'Aix en Provence ( ESA AIX ) -Centre National de la Recherche Scientifique ( CNRS ), Pays germaniques , histoire - culture - philosophie (UMR8547) ( PG,HCP ), Université Paris 8 Vincennes-Saint-Denis ( UP8 ) -Centre National de la Recherche Scientifique ( CNRS ) -Département de Philosophie - ENS Paris, École normale supérieure - Paris ( ENS Paris ) -École normale supérieure - Paris ( ENS Paris ), Perception, Représentations, Image, Son, Musique (PRISM), Aix Marseille Université (AMU)-Ecole supérieure d'Art d'Aix en Provence (ESA AIX)-Centre National de la Recherche Scientifique (CNRS), Pays germaniques , histoire - culture - philosophie (UMR8547) (PG,HCP), Centre National de la Recherche Scientifique (CNRS)-Département de Philosophie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), and VION-DURY, Jean

Subjects
Épistémologie, Hypnose, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Neurosciences, [SHS.PHIL]Humanities and Social Sciences/Philosophy, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SHS.PSY]Humanities and Social Sciences/Psychology, Sciences Cognitives, [SHS.PSY] Humanities and Social Sciences/Psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PHIL] Humanities and Social Sciences/Philosophy, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [ SHS.PHIL ] Humanities and Social Sciences/Philosophy, [ SHS.PSY ] Humanities and Social Sciences/Psychology, Psychanalyse, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH: Hypnosis, Epistemology, Psychoanalysis, Cognitive Sciences, Neuroscience, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
Abstract

This article attempts to present the different theories concerning the hypnotic phenomenon, starting from the principle that hypnosis is rather a major anthropological fact than a simple psychological or consciousness modification, since the hypnotic phenomenon is integrated in social life in many civilizations. For this reason, we approach the question epistemologically, without discarding any theory, and trying to identify what each of them brings to the knowledge of this complex phenomenon.It actually appears that the multiplicity of theories relativizes the strength of each of them. So, in the end, it is very difficult to propose a coherent overall scheme or a unifying theory of what the hypnotic phenomenon is. In a simplified way, two theoretical frameworks face each other: psychological approaches in a broad sense (cognitive psychology, psychoanalysis, social psychology) and physiological approaches (including neurosciences). None of them provides a decisive explanation. Such a proliferation prompts us to consider if, finally, to search an explanation of the hypnotic phenomenon makes sense and if hypnosis could not be a part of the "difficult problem" (or explanatory gap) of the neuroscience concerning consciousness., Cet article tente de faire le point des différentes théories concernant le phénomène hypnotique, en partant du principe qu’il s’agit plus d’un fait anthropologique majeur que d’une simple modification psychologique ou de la conscience, tant le phénomène hypnotique est intégré à une problématique sociale dans de nombreuses civilisations. C’est pourquoi, nous abordons la question de manière épistémologique, sans prendre parti pour telle ou telle théorie et en essayant de dégager ce que chacune d’entre elle apporte à la connaissance de ce phénomène complexe.Il apparait en réalité que la multiplicité des théories relativise la force de chacune d’elle, et que, au bout du compte, il est bien difficile de proposer un schéma d’ensemble cohérent ou une théorie unificatrice de ce qu’est le phénomène hypnotique. De manière simplifiée, deux cadres théoriques se font face : les approches psychologiques au sens large (psychologie cognitive, psychanalyse, psychologie sociale) et les approches physiologiques (dont les neurosciences) sans qu’aucune d’elle n’apporte d’explication décisive. Une telle prolifération incite à se demander si finalement envisager une explication du phénomène hypnotique a un sens et si l’on n’est pas avec l’hypnose au cœur du « problème difficile » (ou fossé explicatif) des neurosciences concernant la conscience.

Published
2018

13. Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort

Author

Fond , G., Boyer , L., Schürhoff , F., Berna , F., Godin , O., Bulzacka , E., Andrianarisoa , M., Brunel , L., Aouizerate , B., Capdevielle , D., Chereau , I., Coulon , N., d'Amato , T., Dubertret , C., Dubreucq , J., Faget , C., Lançon , C., Leignier , S., Mallet , J., Misdrahi , D., Passerieux , C., Rey , R., Schandrin , A., Urbach , M., Vidailhet , P., Llorca , P., Leboyer , M., Bazin , N., Blanc , O., Chereau-Boudet , I., Chesnoy-Servanin , G., Danion , M., Deloge , A., Denizot , H., Dorey , M., Fluttaz , C., Fonteneau , S., Gabayet , F., Giraud-Baro , E., Jarroir , M., Lacelle , D., Laouamri , H., Le Gloahec , T., Le Strat , Y., Metairie , E., Offerlin-Meyer , I., Peri , P., Pires , S., Portalier , C., Ramet , L., Roman , C., Tessier , A., Tronche , A., Vaillant , F., Vehier , A., Vila , E., Yazbek , H., Zinetti-Bertschy , A., CHU Pontchaillou [Rennes], Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Européen des membranes ( IEM ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure de Chimie de Montpellier ( ENSCM ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Université de Montpellier ( UM ), Université Montpellier 1 ( UM1 ), Institut d'Electronique et de Télécommunications de Rennes ( IETR ), Université de Nantes ( UN ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National des Sciences Appliquées - Rennes ( INSA Rennes ) -CentraleSupélec-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier le Vinatier [Bron], Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Génétique moléculaire de la neurotransmission et des processus neurodégénératifs ( LGMNPN ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), ONERA - The French Aerospace Lab ( Toulouse ), ONERA, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies ( FEMTO-ST ), Université de Technologie de Belfort-Montbeliard ( UTBM ) -Ecole Nationale Supérieure de Mécanique et des Microtechniques ( ENSMM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Laboratoire de Physique Nucléaire et de Hautes Énergies ( LPNHE ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Techniques of Informatics and Microelectronics for integrated systems Architecture ( TIMA ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -Institut National Polytechnique de Grenoble ( INPG ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Centre Hospitalier d'Annecy, Centre hospitalier d'Annecy, IHU-LIRYC, and Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

14. Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality

Author

Roux , Paul, Misdrahi , David, Capdevielle , Delphine, Aouizerate , Bruno, Berna , Fabrice, Brunel , Lore, Chéreau , Isabelle, Dorey , Jean-Michel, Dubertret , Caroline, Dubreucq , Julien, Faget-Agius , Catherine, Fonteneau , Sandrine, Gabayet , Franck, Llorca , Pierre, Mallet , Jasmina, Rey , Romain, Richieri , Raphaëlle, Schandrin , Aurélie, Schürhoff , Franck, Tessier , Arnaud, Vidailhet , Pierre, Passerieux , Christine, Urbach , Mathieu, Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Fondation FondaMental [Créteil], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier Charles Perrens [Bordeaux], Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Service de psychiatrie, CHU Clermont-Ferrand, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris 1 Panthéon-Sorbonne - École d'Histoire (UP1 UFR09), Université Paris 1 Panthéon-Sorbonne (UP1), Neuropsychologie Cognitive et Prise en Charge des Troubles de la Communication Schizophreniques, Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Perrens, Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 1 Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Laboratoire de neuropsychologie cognitive et prise en charge des troubles de la communication schizophrénique ( EA 4047 ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Fédération de Médecine Translationnelle de Strasbourg ( FMTS ), Université de Strasbourg ( UNISTRA ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants ( SPMC ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Aix Marseille Université ( AMU ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université Panthéon-Sorbonne - UFR Histoire ( UP1 UFR09 ), Université Panthéon-Sorbonne ( UP1 ), Neuropsychologie Cognitive et prise en Charge des Troubles de la Communication schizophréniques, and Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Pierre et Marie Curie - Paris 6 ( UPMC )

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Objective: The relationship between greater insight and increased risk of suicide in patients with schizophrenia is debated. The purpose of this study was to assess whether quality of life (QoL) and depression mediated the association between insight and suicidality. Methods: Between March 2010 and December 2015, 527 community-dwelling adults with stable schizophrenia according to DSM-IVcriteria were included in a multicenter cross-sectional study, the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Structural equation modeling was used for mediation analyses among insight, QoL, depression, and suicidality, controlling for the global level of schizophrenic symptoms. Results: The model provided a good fit for the data ( (chi32 =1.4, P = .708, Tucker-Lewis index = 1, comparative fit index =1, root mean square error of approximation =0, standardized root mean square residual =0.008) and explained 27% of the variance in suicidality. Poorer QoL and greater severity of depression mediated 68.4% of the positive association between insight and suicidality (full mediation). Poorer QoL mediated 48% of the positive effect of insight on depression (partial mediation). The severity of depression mediated 91.2% of the negative relationship between QoL and suicidality (full mediation). Conclusions: Insight appears to be an indirect risk factor for suicide in patients with schizophrenia, with the link being mediated by poorer QoL and worse underlying depression, mainly by a sequential pathway but also by a less important parallel pathway.

Published
2018

15. Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)

Author

Olivier Blanc, L. Samalin, Laurent Boyer, Pierre-Michel Llorca, Mocrane Abbar, M Honciuc, I. de Chazeron, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), CHU Pontchaillou [Rennes], and Service de psychiatrie A1, centre hospitalo-universitaire de Nîmes, 30900 Nîmes, France.

Subjects
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, law.invention, Study Protocol, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Randomized controlled trial, law, Patient-Centered Care, lcsh:Psychiatry, Clinical endpoint, Medicine, 030212 general & internal medicine, Cluster randomised controlled trial, ComputingMilieux_MISCELLANEOUS, Maintenance treatment, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 3. Good health, Therapeutic relationship, Psychiatry and Mental health, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, medicine.symptom, Mania, Adult, medicine.medical_specialty, Bipolar disorder, lcsh:RC435-571, Cluster randomized trial, Clinical Decision-Making, Decision Making, Decision Support Techniques, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Quality of life (healthcare), Humans, Medication adherence, Shared decision-making, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, 030227 psychiatry, Mood, Decision aid, Family medicine, Quality of Life, Patient Compliance, Patient Participation, business
Abstract

Background Shared decision-making (SDM) is a model of interaction between doctors and patients in which both actors contribute to the medical decision-making process. SDM has raised great interest in mental healthcare over the last decade, as it is considered a fundamental part of patient-centered care. However, there is no research evaluating the efficacy of SDM compared to usual care (CAU), as it relates to quality of care and more specifically treatment adherence, in bipolar disorder (BD). Methods/Design This is a 12-month multi-centre, cluster-randomized controlled trial comparing the efficacy of SDM to CAU. Adult BD patients (n = 300) will be eligible after stabilization for at least 4 weeks following an acute mood episode. The intervention will consist of applying the standardized SDM process as developed by the Ottawa Hospital Research Institute in order to choose the maintenance treatment of BD. A multidisciplinary team developed a decision aid “choose my long-term treatment with my doctor” for BD patients to clarify possible therapeutic options. Primary outcome will assess the patient’s level of adherence (based on hetero-evaluation) of ongoing treatment at 12 months. Secondary outcomes will assess the difference between the 2 groups of patients in terms of adherence to maintenance drug therapy based on other measures (self-assessment scale and plasma levels of mood stabilizers). Additionally, other dimensions will be assessed: decisional conflict, satisfaction with care and involvement in decision making, beliefs about treatment, therapeutic relationship, knowledge about information for medical decision and clinical outcomes (depression, mania, functioning and quality of life). The primary endpoint will be analysed without adjustment by comparison of adherence scores between the two groups using Student t-tests or Mann–Whitney tests according to the variable distribution. A set of secondary analyses will be adjusted for covariates of clinical interest using generalized linear mixed regression models. Discussion This will be the first study evaluating the effect of an SDM intervention on patient adherence in BD. This is also an innovative protocol because it proposes the development of an evidence-based tool that should help patients and clinicians to initiate discussions regarding the use of BD treatment. Trial registration The study has been registered with ClinicalTrials.gov as NCT03245593.

Published
2018

16. Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?

Author

Frédéric Dutheil, Yves Boirie, Ana Marques, Elodie Durand, Maria Livia Fantini, Franck Durif, Isabelle Rieu, Aurélien Mulliez, Groupe de sociologie politique et morale (GSPM), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne (LAPSCO), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), École d’Orthoptie - Clermont-Ferrand (EO - UdA), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), CHU Clermont-Ferrand, Unité de Biostatistiques, Délégation Recherche Clinique & Innovation, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Groupe de sociologie politique et morale ( GSPM ), École des hautes études en sciences sociales ( EHESS ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne ( LAPSCO ), Université Clermont Auvergne ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), École d’Orthoptie - Clermont-Ferrand ( EO - UdA ), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I ( UdA ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Unité de Nutrition Humaine ( UNH ), Institut National de la Recherche Agronomique ( INRA ) -Université d'Auvergne - Clermont-Ferrand I ( UdA ) -Clermont Université, Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Institut National de la Recherche Agronomique (INRA), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
0301 basic medicine, Blood Glucose, Male, Parkinson's disease, Dopamine, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Administration, Oral, Neurodegenerative disease, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Insulin, ComputingMilieux_MISCELLANEOUS, 2. Zero hunger, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Diabetes, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Parkinson Disease, Middle Aged, 3. Good health, Neurology, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, medicine.symptom, medicine.drug, medicine.medical_specialty, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Internal medicine, Diabetes mellitus, medicine, Humans, Aged, Glucose Metabolism Disorders, Retrospective Studies, Autonomous nervous system, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Dysautonomia, Metabolism, Glucose Tolerance Test, medicine.disease, 030104 developmental biology, Endocrinology, Autonomic Nervous System Diseases, Blood sugar regulation, Neurology (clinical), Geriatrics and Gerontology, business, Body mass index, 030217 neurology & neurosurgery
Abstract

Objective To detect changes in glucose regulation in moderate to advanced Parkinson's disease (PD) patients in response to oral glucose intake. Methods Blood glucose and insulin kinetics during a 75-g Oral Glucose Tolerance Test (OGTT) were compared between 50 PD patients and 50 healthy controls (CT) matched for body mass index (BMI), age and sex. Potential relationships between changes in glucose kinetics and clinical parameters were analyzed including Parkinson's disease severity and autonomic function using SCOPA-AUT (Scales for Outcomes in Parkinson's disease, Autonomic dysfunction). Results Blood glucose was significantly higher at T90 (p = 0.04) and T150 (p = 0.01) in PD patients compared to healthy matched controls. Moreover, the total area under time curve (AUC) for the blood glucose levels was significantly higher in PD patients compared to healthy controls (1187 ± 229 vs 1101 ± 201 mmol min.l-1; p = 0.05). Simultaneously, no significant increase of insulin levels was observed in PD patients compared to controls. Higher blood glucose levels were associated with higher BMI (p Conclusion Glucose control is impaired in moderate to advanced non-diabetic PD patients, due to impaired adaptive insulin response which may be a novel non-motor consequence of PD associated dysautonomia.

Published
2018

17. Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort

Author

Laurent Boyer, Christine Passerieux, Pierre Vidailhet, Delphine Capdevielle, Thierry d'Amato, A. Schandrin, Lore Brunel, Isabelle Chereau, N Coulon, Bruno Aouizerate, David Misdrahi, E. Bulzacka, Catherine Faget, Sylvain Leignier, Julien Dubreucq, Guillaume Fond, Franck Schürhoff, Mathieu Urbach, M. Andrianarisoa, Caroline Dubertret, Marion Leboyer, Pierre-Michel Llorca, Christophe Lançon, Jasmina Mallet, Hélène Denizot, Romain Rey, Ophélia Godin, Fabrice Berna, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Fondation FondaMental [Créteil], Université Pierre et Marie Curie - Paris 6 (UPMC), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Hôpital Charles Perrens, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de psychiatrie, CHU Clermont-Ferrand, Psychopathologie et neurobiologie de la schizophrénie et de la vulnérabilité à la psychose, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de Psychiatrie D Adultes, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Neuropsychologie Cognitive et Prise en Charge des Troubles de la Communication Schizophreniques, Institut National de la Santé et de la Recherche Médicale (INSERM), FondaMental Foundation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Albert Chenevier-Fondation de Coopération Scientifique, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Institut National de la Santé et de la Recherche Médicale, AP-HM, Fondation FondaMental, Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants ( SPMC ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Aix Marseille Université ( AMU ), Universite ́ Pierre et Marie Curie-Paris, F-75005, Paris, Fédération de Médecine Translationnelle de Strasbourg ( FMTS ), Université de Strasbourg ( UNISTRA ), Institut d'Electronique et de Télécommunications de Rennes ( IETR ), Université de Nantes ( UN ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National des Sciences Appliquées - Rennes ( INSA Rennes ) -CentraleSupélec-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hôpital Sainte-Marguerite [CHU - APHM] ( Hôpitaux Sud ), Neuropsychologie Cognitive et prise en Charge des Troubles de la Communication schizophréniques, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Albert Chenevier-Fondation de Coopération Scientifique, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre hospitalier Charles Perrens [Bordeaux], and Université Claude Bernard Lyon 1 (UCBL)

Subjects
Male, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, medicine.medical_treatment, Comorbidity, Anxiety, Childhood trauma, Cohort Studies, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Benzodiazepines, 0302 clinical medicine, Prevalence, ComputingMilieux_MISCELLANEOUS, Depression (differential diagnoses), media_common, Physical pain, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Depression, Headache, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Antidepressive Agents, 3. Good health, Adult Survivors of Child Adverse Events, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Cohort, Antidepressant, Female, medicine.symptom, Antipsychotic Agents, Adult, medicine.medical_specialty, medicine.drug_class, media_common.quotation_subject, Pain, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Internal medicine, medicine, Humans, Antipsychotic, Biological Psychiatry, Pharmacology, Benzodiazepine, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Addiction, medicine.disease, 030227 psychiatry, Cross-Sectional Studies, Self Report, business, 030217 neurology & neurosurgery
Abstract

Introduction Little is known about perception of physical pain in schizophrenia (SZ). Some studies have suggested that patients with SZ may have an increased pain threshold, while others have suggested that patients with SZ may suffer from undetected and untreated high physical pain levels. The objectives of this study were (i) to investigate the prevalence of self-reported physical pain in stabilized SZ subjects, and (ii) to determine whether physical pain was associated with psychiatric characteristics and somatic comorbidities (iii) to determine whether antidepressants and benzodiazepine administration were associated with lower self-reported pain. Method 468 community-dwelling stable SZ subjects (73% men, mean aged 32 years) were recruited in the Schizophrenia Expert Center national network. Patients with moderate to extreme pain, assessed with the EQ5D-5L questionnaire, were classified as belonging to the “pain group”. Results 104 (22.2%) reported moderate to extreme pain levels. In multivariate analysis, pain has been associated with headache (OR = 2.63 [1.04–6.63], p = 0.04), higher anxiety (OR = 1.61 [1.18–2.21], p = 0.003), higher current depressive symptoms (OR = 1.09 [1.01–1.17], p = 0.03), history of childhood trauma (1.03 [1.01–1.06], p = 0.01) and older age (OR = 1.04 [1.01–1.07], p = 0.03), independently of current psychotic severity, sociodemographic variables, antipsychotic, antidepressant and benzodiazepine treatments. No association with addictive behaviors or illness characteristics has been found. Conclusion The present findings suggest that community-dwelling SZ outpatients report a high rate of self-reported physical pain, associated with headache, depression and anxiety and history of childhood trauma. Physical pain should be systematically assessed and specifically treated, when needed, in patients with SZ.

Published
2018

18. Driver's emotional state and detection of vulnerable road users: towards a better understanding of how emotions affect drivers' perception using cardiac and ocular metrics

Author

Joceline Rogé, Alex Lafont, Jean-Michel Boucheix, Daniel Ndiaye, Laboratoire Ergonomie et Sciences Cognitives pour les Transports ( IFSTTAR/TS2/LESCOT ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Université de Lyon, Laboratoire Exploitation, Perception, Simulateurs et Simulations ( IFSTTAR/COSYS/LEPSIS ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Communauté Université Paris-Est, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] ( LEAD ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Ergonomie et Sciences Cognitives pour les Transports (IFSTTAR/TS2/LESCOT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Université de Lyon, Laboratoire Exploitation, Perception, Simulateurs et Simulations (IFSTTAR/COSYS/LEPSIS), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Communauté Université Paris-Est, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), and Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)

Subjects
media_common.quotation_subject, Applied psychology, USAGER VULNERABLE DE LA ROUTE, Transportation, COLERE, Anger, DRIVING SIMULATION, Affect (psychology), 050105 experimental psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, 0302 clinical medicine, Perception, EYE-TRACKING, ANGER, 0501 psychology and cognitive sciences, CLIPS, Applied Psychology, Civil and Structural Engineering, media_common, computer.programming_language, Road user, Visual search, Attention management, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 05 social sciences, HEART RATE VARIABILITY, VULNERABLE ROAD USERS, AUTONOMIC NERVOUS SYSTEM, SIMULATEUR DE CONDUITE, Automotive Engineering, Eye tracking, Psychology, computer, human activities, 030217 neurology & neurosurgery, SIMULATEUR (CONDUITE)
Abstract

Traditionally, anger has been considered to have a detrimental effect on driving. However, recent studies suggest that this statement should be qualified, especially where vulnerable road user detection is concerned. One primary factor which may determine anger’s effect on a driver’s attention is its intensity. In the present study, different intensities of anger were elicited via film clips, then performances in vulnerable road user detection (i.e., of cyclists) were assessed while participants drove a car in a simulated environment. Cardiac and ocular measurements and self-reported data were used in order to accurately assess emotional state and attention management throughout the experiment. Results suggested that participants resorted to reappraisal strategies when they were exposed to the emotional film clips. This phenomenon did not directly affect cyclist detection performances, but evidence of different visual scanning strategies between groups emerged. The contribution of cardiac and ocular measurements to emotional assessment and the advantages of appraisal approaches of emotion were also discussed.

Published
2018

19. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)

Author

Philippe Le Corvoisier, Jules Alexandre Desmeules, Célia Lloret-Linares, Jean-Luc Cracowski, Wissam El-Hage, L. Yon, Kyle Heron, Frank Bellivier, Frédéric Haesebaert, Siamak Davani, Damien Montange, Thomas Desmidt, Olivier Doumy, Antoine Yrondi, Fanny Moliere, Raphaëlle-Marie Richieri, Philippe Vignaud, Sophie Morange, Marie Besson, Sylvie Chevret, Isabelle Nieto, Marion Leboyer, Jérôme Holtzmann, F. Galtier, Fabienne Calvas, Julien Déglon, Pierre-Michel Llorca, Emmanuel Haffen, Philippe Courtet, Youssef Daali, Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de pharmacologie et innovation dans le diabète ( CPID ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Centre National de la Recherche Scientifique ( CNRS ), Centre d'Investigation Clinique ( CIC ), Hospices Civils de Lyon ( HCL ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU de Lyon, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Clinique Psychiatrique Universitaire [Tours], CHRU Tours, Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire ( HP2 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), CIC - CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), UR 1341 Alimentation et adaptations digestives, nerveuses et comportementales, Institut National de la Recherche Agronomique ( INRA ) -Alimentation Humaine ( ALIM.H ) -Alimentation et adaptations digestives, nerveuses et comportementales ( ADNC ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Geneva University Hospital (HUG), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance Publique - Hôpitaux de Marseille (APHM), CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Laval [Québec] (ULaval), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre d'Investigation Clinique [Grenoble] (CIC Grenoble ), CHU Grenoble-Hôpital Michallon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Fondation FondaMental [Créteil], CHU Toulouse [Toulouse], Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre d'investigation clinique de Toulouse (CIC 1436), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Bordeaux [Bordeaux], University of Bristol [Bristol], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Lausanne University Hospital, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Douhairie, Marie-Laurence, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
Male, Oncology, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Venlafaxine, Pharmacology, 030226 pharmacology & pharmacy, ATP-Binding Cassette, Sub-Family B, Member 1/metabolism, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Second-Generation/blood, Antidepressive Agents, Second-Generation/pharmacokinetics, Antidepressive Agents, Second-Generation/therapeutic use, Cytochrome P-450 CYP2C19/metabolism, Cytochrome P-450 CYP2D6/metabolism, Cytochrome P-450 CYP3A/metabolism, Depressive Disorder, Major/drug therapy, Depressive Disorder, Major/metabolism, Female, France, Genotype, Humans, Middle Aged, Phenotype, Switzerland, Treatment Outcome, Venlafaxine Hydrochloride/blood, Venlafaxine Hydrochloride/pharmacokinetics, Venlafaxine Hydrochloride/therapeutic use, Young Adult, Study Protocol, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, 80 and over, Cytochrome P-450 CYP3A, Medicine, Pharmacology (medical), Major depressive episode, ComputingMilieux_MISCELLANEOUS, ddc:615, ddc:617, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Venlafaxine Hydrochloride, Area under the curve, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Antidepressive Agents, 3. Good health, Cytochrome P-450 CYP2D6, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Antidepressive Agents, Second-Generation, medicine.symptom, medicine.drug, CYP2D6, medicine.medical_specialty, Major/drug therapy/metabolism, CYP2C19, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Pharmacokinetics, lcsh:RA1190-1270, Internal medicine, Member 1/metabolism, ATP Binding Cassette Transporter, Subfamily B, Member 1, Dosing, lcsh:Toxicology. Poisons, Second-Generation/blood/pharmacokinetics/therapeutic use, Depressive Disorder, Depressive Disorder, Major, Sub-Family B, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, lcsh:RM1-950, [SCCO.NEUR] Cognitive science/Neuroscience, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Cytochrome P-450 CYP2C19, lcsh:Therapeutics. Pharmacology, Venlafaxine Hydrochloride/blood/pharmacokinetics/therapeutic use, ATP-Binding Cassette, Personalized medicine, business, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 030217 neurology & neurosurgery
Abstract

It is well known that the standard doses of a given drug may not have equivalent effects in all patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence the burden and costs of mood depressive disorders. The Geneva Cocktail Phenotypic approach presents several advantages including the “in vivo” measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis. The goal of this project is to explore the relationship between the activity of drug-metabolizing enzymes (DME), assessed by a phenotypic approach, and the concentrations of Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV), the efficacy and tolerance of VLX. This study is a multicentre prospective non-randomized open trial. Eligible patients present a major depressive episode, MADRS over or equal to 20, treatment with VLX regardless of the dose during at least 4 weeks. The Phenotype Visit includes VLX and ODV concentration measurement. Following the oral absorption of low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine, drug metabolizing enzymes activity is assessed by specific metabolite/probe concentration ratios from a sample taken 2 h after cocktail administration for CYP2C19, CYP3A4, CYP2D6; and by the determination of the limited area under the curve from the capillary blood samples taken 2–3 and 6 h after cocktail administration for CYP2C19 and P-gp. Two follow-up visits will take place between 25 and 40 days and 50–70 days after inclusion. They include assessment of efficacy, tolerance and observance. Eleven french centres are involved in recruitment, expected to be completed within approximately 2 years with 205 patients. Metabolic ratios are determined in Geneva, Switzerland. By showing an association between drug metabolism and VLX concentrations, efficacy and tolerance, there is a hope that testing drug metabolism pathways with a phenotypical approach would help physicians in selecting and dosing antidepressants. The MARVEL study will provide an important contribution to increasing the knowledge of VLX variability and in optimizing the use of methods of personalized therapy in psychiatric settings. ClinicalTrials.gov NCT02590185 (10/27/2015). This study is currently recruiting participants.

Published
2017

20. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Author

Dufouil , Carole, Dubois , Bruno, Vellas , Bruno, Pasquier , Florence, Blanc , Frédéric, Hugon , Hugo, Hanon , Olivier, Dartigues , Jean-François, Harston , Sandrine, Gabelle , Audrey, Ceccaldi , Mathieu, Beauchet , Olivier, Krolak-Salmon , Pierre, David , David, Rouaud , Olivier, Godefroy , Olivier, Belin , Catherine, Rouch , Isabelle, Auguste , Nicolas, Wallon , David, Benetos , Athanase, Pariente , Jeremie, Paccalin , Marc, Moreaud , Olivier, Hommet , Caroline, Sellal , François, Boutoleau-Bretonnière , Claire, Jalenques , Isabelle, Gentric , Armelle, Vandel , Pierre, Azouani , Chabha, Fillon , Ludovic, Fischer , Clara, Savarieau , Helen, Operto , Grégory, Bertin , Hugo, Chupin , Marie, Bouteloup , Vincent, Habert , Marie-Odile, Mangin , Jean-François, Chêne , Geneviève, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hématopoïèse normale et pathologique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Laboratoire de physique de la matière condensée (LPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Groupe hospitalier Broca, CHU Bordeaux [Bordeaux], Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Service de neurologie et de neuropsychologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire de Psychologie des Pays de la Loire (LPPL), Université d'Angers (UA)-Université de Nantes - UFR Lettres et Langages (UFRLL), Université de Nantes (UN)-Université de Nantes (UN), Hospices Civils de Lyon (HCL), Centre Mémoire de Ressources et de Recherche [Nice] (CMRR Nice), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire de génie des procédés - environnement - agroalimentaire (GEPEA), Mines Nantes (Mines Nantes)-Université de Nantes - Faculté des Sciences et des Techniques, Université de Nantes (UN)-Université de Nantes (UN)-Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Système Nerveux Autonome - Epidémiologie, Physiologie, Ingénierie, Santé (SNA-EPIS), Université Jean Monnet [Saint-Étienne] (UJM)-Centre Hospitalier Universitaire de Saint-Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), CHU Rouen, Normandie Université (NU), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Toulouse Neuro Imaging Center (ToNIC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire de Psychologie et NeuroCognition (LPNC), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [Strasbourg], CHU Strasbourg-Hopital Civil, Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), CATI Multicenter Neuroimaging Platform (CATI), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Algorithms, models and methods for images and signals of the human brain (ARAMIS), Sorbonne Université (SU)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Neuroimagerie Assistée par Ordinateur (LNAO), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université de Bordeaux (UB), Pôle de Santé publique [CHU Bordeaux], CHU de bordeaux, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Fédération des Centres Mémoire de Ressource et de Recherche du Sud de la France [CHU Toulouse] (F-CMRR-SF), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Mémoire de Ressources et de Recherche [Lille-Bailleul] (CMRR), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Roger Salengro [Lille], Centre Mémoire de Ressources et de Recherches [Bordeaux], Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Centre de Mémoire de Ressources et de Recherche [Paris Nord], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Sorbonne Paris Cité (USPC), Maladie d'Alzheimer : marqueurs génétiques et vasculaires, neuropsychologies (EA 4468), Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca, Centre de Mémoire de Ressources et de Recherche [Paris Broca], AP-HP - Hôpital Broca [Paris], Centre de Mémoire de Ressources et de Recherche [Hôpital Pellegrin, Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin [Bordeaux], Centre de Mémoire de Ressources et de Recherche [Hôpital Xavier Arnozan, Bordeaux], Hôpital Xavier Arnozan - CHU de Bordeaux, Centres Mémoire de Ressources et de Recherche [Hôpital Gui de Chauliac, Montpellier] (CMRR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac, Centre de Mémoire de Ressources et de Recherche [Hôpital La Timone, Marseille], Hôpital de la Timone [CHU - APHM] (TIMONE)-CHU Marseille, Centre Mémoire de Ressources et de Recherche [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre Mémoire de Ressources et de Recherche [Lyon] (CMRR), Hospices Civils de Lyon (HCL)-Hôpital des Charpennes [CHU - HCL], Cognition Behaviour Technology (CobTek), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Centre Mémoire Ressources et Recherche [Dijon] (CMRR Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Mémoire de Ressources et de Recherche [CHU Amiens], Clinique de la Mémoire [Hôpitaux Universitaires Paris-Seine-Saint-Denis], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital Nord], CHU de Saint-Étienne Hôpital Nord [Saint Etienne], Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital de la Charité], CHU de Saint-Étienne Hôpital la Charite, Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Centre Mémoire de Ressources et de Recherche [CHU de Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Mémoire [CHU de Toulouse], Centre Mémoire de Ressources et de Recherche [CHRU de Poitiers La Miletrie], CHRU de Poitiers La Miletrie [Poitiers], Centre Mémoire de Ressources et de Recherche [CHU Grenoble Alpes-Site NORD, La Tronche], CHU Grenoble Alpes - Site NORD [La Tronche], Centre Mémoire de Ressources et de Recherche [CHRU de Tours Hôpital Bretonneau], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau [Tours], Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Mémoire de Ressources et de Recherche [Hôpitaux Civils de Colmar, Strasbourg], Hôpitaux Civils de Colmar, Centre Mémoire de Ressources et de Recherche [CHU de Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Mémoire de Ressources et de Recherche [CHU Clermont-Ferrand] (CMRR), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Mémoire de Ressources et de Recherche [CHRU de Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Mémoire de Ressources et de Recherche [CHRU de Besançon] (CMRR), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques [CHRU de Besançon], Centre pour l’Acquisition et le Traitement des Images [Saclay] (CATI), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut d'imagerie biomédicale (I²BM), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay, The MEMENTO cohort was sponsored by the Fondation Plan Alzheimer (Alzheimer Plan 2008–2012). This work was also supported by the following : CIC 1401-EC, Bordeaux University Hospital, Inserm and the University of Bordeaux., on behalf of the MEMENTO cohort Study Group, BMC, BMC, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne] (CMRR 42), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Université Côte d'Azur (UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA), Mines Nantes (Mines Nantes)-Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Laboratoire de Psychologie et NeuroCognition (LPNC ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut d'imagerie biomédicale (I²BM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Toulouse - CHU Toulouse-Hôpital La Grave-Casselardit [Toulouse], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Gui de Chauliac-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice), Centre Mémoire de Ressources et de Recherche [CHU de Toulouse, Hôpital Purpan], Hôpital Purpan [Toulouse], Hôpital Bretonneau [Tours]-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), INSERM Unit 708-Neuroepidemiology, Paris, France, Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] ( IM2A ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Epidémiologie et anlyses en santé publique: risques, maladies chroniques et handicaps, Université Paul Sabatier - Toulouse 3 ( UPS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Neurologie [Lille], Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Kalray, Service de gériatrie, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR99-ISPED, Institut de recherche en biothérapie ( IRB ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Université de Montpellier ( UM ), Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Département de Médecine Interne et Gérontologie clinique, CHU Angers, Centre de recherche en neurosciences de Lyon ( CRNL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de génie des procédés - environnement - agroalimentaire ( GEPEA ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Nantes ( UN ) -IMT Atlantique Bretagne-Pays de la Loire ( IMT Atlantique ) -Université Bretagne Loire ( UBL ) -Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique ( ONIRIS ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), AP-HP Hôpital Avicenne [Bobigny], Centre Hospitalier Universitaire de Saint-Etienne ( CHU de Saint-Etienne ), Risque cardiovasculaire, rigidité-fibrose et hypercoagulabilité ( RCV ), Université Henri Poincaré - Nancy 1 ( UHP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Imagerie cérébrale et handicaps neurologiques, Centre Mémoire de Ressources et de Recherche ( CM2R ), CHU de Poitiers-Hôpital Jean Bernard, Unité de Neuropsychologie, CHU Grenoble, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Nantes ( UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôpital Nord Laënnec, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Service de Médecine Interne Gériatrique ( BREST - SMIG ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'Acquisition et de Traitement des Images [Paris], Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Service NEUROSPIN ( NEUROSPIN ), Direction de Recherche Fondamentale (CEA) ( DRF (CEA) ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Bordeaux population health ( BPH ), Université de Bordeaux ( UB ) -Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Jacques-Louis Lions ( LJLL ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Epidemiologie-Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Bordeaux Ségalen [Bordeaux 2], Service de médecine nucléaire [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Laboratoire de Neuroimagerie Assistée par Ordinateur ( LNAO ), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université de Bordeaux (UB), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Hôpital Bretonneau [Tours], Centre Mémoire de Ressources et de Recherche [CHU de Clermont-Ferrand], CHU Clermont-Ferrand, Centre Mémoire de Ressources et de Recherche [CHRU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz-Hôpital Saint-Jacques [CHRU de Besançon], Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Service NEUROSPIN (NEUROSPIN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut d'imagerie biomédicale (I²BM), Sorbonne Université, Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut d'imagerie biomédicale (I²BM), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA), Groupe hospitalier Pellegrin [Bordeaux] -CHU Bordeaux [Bordeaux], COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice)-Université Côte d'Azur (UCA), CHU Lille, CNRS, Inserm, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U1171, Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Fédération des Centres Mémoire de Ressource et de Recherche du Sud de la France [CHU Toulouse] ( F-CMRR-SF ), Troubles cognitifs dégénératifs et vasculaires ( DN2M ), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ) -INSERM, Centre Mémoire de Ressources et de Recherche [Lille-Bailleul] ( CMRR ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ) -Hôpital Roger Salengro [Lille], Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie ( ICube ), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg ( ENGEES ) -Université de Strasbourg ( UNISTRA ) -Institut National des Sciences Appliquées - Strasbourg ( INSA Strasbourg ), Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Centre National de la Recherche Scientifique ( CNRS ) -Matériaux et nanosciences d'Alsace, Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Réseau nanophotonique et optique, Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Sorbonne Paris Cité ( USPC ), Maladie d'Alzheimer : marqueurs génétiques et vasculaires, neuropsychologie ( EA 4468 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Groupe hospitalier Broca, Centre Hospitalier Universitaire de Bordeaux-Groupe hospitalier Pellegrin [Bordeaux], Centres Mémoire de Ressources et de Recherche [Hôpital Gui de Chauliac, Montpellier] ( CMRR ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Gui de Chauliac, Hôpital de la Timone [CHU - APHM] ( TIMONE ) -CHU Marseille, Centre Mémoire de Ressources et de Recherche [Lyon] ( CMRR ), Hospices Civils de Lyon ( HCL ) -Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon ( HCL ), Cognition Behaviour Technology ( CobTek ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -CHU Nice-Institut Claude Pompidou [Nice] ( ICP - Nice ), Centre Mémoire de Ressources et de Recherche [Nice] ( CMRR Nice ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -CHU Nice, Centre Mémoire Ressources et Recherche [Dijon] ( CMRR Dijon ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), CHU Amiens Picardie - Site Nord (Hôpital Nord) [Amiens], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ) -Hôpital Bretonneau [Tours], Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean-Minjoz [CHRU de Besançon]-Hôpital Saint-Jacques [CHRU de Besançon], Centre pour l’Acquisition et le Traitement des Images [Saclay] ( CATI ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -NeuroSpin-Institut d'imagerie biomédicale (I²BM), Sorbonne Universités, Département de Médecine Nucléaire [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [APHP], Laboratoire d'Imagerie Biomédicale ( LIB ), and Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC )

Subjects
Male, [SDV]Life Sciences [q-bio], Neuroimaging, Neuropsychological Tests, Spinal Puncture, Pattern Recognition, Automated, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Diagnostic Self Evaluation, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cognitive aging, Fluorodeoxyglucose F18, Image Processing, Computer-Assisted, Humans, Cognitive Dysfunction, Longitudinal Studies, ComputingMilieux_MISCELLANEOUS, Aged, [ SDV ] Life Sciences [q-bio], Cohort studies, Natural history studies (prognosis), Alzheimer''s disease, Research, Brain, Organ Size, Magnetic Resonance Imaging, [SDV] Life Sciences [q-bio], Research Design, Positron-Emission Tomography, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, France, Radiopharmaceuticals, Alzheimer’s disease, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract

Background The natural history and disease mechanisms of Alzheimer’s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to scrutinise patients as early as needed and to use integrative approaches combining standardised, repeated clinical investigations and cutting-edge biomarker measurements. Methods In the nationwide French MEMENTO cohort study, participants were recruited in memory clinics and screened for either isolated subjective cognitive complaints (SCCs) or mild cognitive impairment (MCI; defined as test performance 1.5 SD below age, sex and education-level norms) while not demented (Clinical Dementia Rating [CDR]

Published
2017

21. Le concept d’identité culturelle chez les enfants adoptés : quelle pertinence ?

Author

Anne Revah-Levy, Sara Skandrani, Aurélie Harf, Marie Rose Moro, Eglantine Mazeaud, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Centre de Soins Psychothérapeutiques de Transition pour Adolescents, Hôpital d’Argenteuil, Maison de Solenn [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], and Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 4. Education, 05 social sciences, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, 050109 social psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, Psychiatry and Mental health, [SCCO.PSYC]Cognitive science/Psychology, Developmental and Educational Psychology, 0501 psychology and cognitive sciences, [No keyword], ComputingMilieux_MISCELLANEOUS, 050104 developmental & child psychology
Abstract

La notion d’identite culturelle des enfants adoptes a l’etranger a ete largement etudiee aux Etats-Unis, tres peu en France. Il a donc semble pertinent de realiser une revue de la litterature anglo-saxonne sur ce theme afin d’en degager les principaux axes de reflexion. Malgre un parti pris net en faveur de l’importance, pour l’enfant, du maintien de liens avec la culture du pays de naissance, les resultats des etudes ne sont pas consensuels. Une discussion autour de la methodologie et des resultats de ces etudes est menee avant de conclure sur la position defendue a la consultation « adoption internationale » de la Maison des Adolescents de l’hopital Cochin : l’importance de decliner et complexifier la question culturelle pour mettre au travail ce qu’elle recouvre : question des origines, question de l’alterite et place de l’enfant sur l’axe filiatif et affiliatif. Des exemples, sous forme de citations, issues des consultations adoption, permettront d’illustrer ces propos.

Published
2015

22. Quels liens gardent les parents adoptants avec la culture du pays de naissance de leur enfant ? Une approche qualitative

Author

Camille Zimmerman, Eglantine Mazeaud, Marie Rose Moro, Sara Skandrani, Aurélie Harf, Claire Mestre, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), association Mana Bordeaux, CHU Bordeaux [Bordeaux], Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Maison de Solenn [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 4. Education, 05 social sciences, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, [SCCO.PSYC]Cognitive science/Psychology, Pediatrics, Perinatology and Child Health, Developmental and Educational Psychology, 0501 psychology and cognitive sciences, [No keyword], 030212 general & internal medicine, 10. No inequality, ComputingMilieux_MISCELLANEOUS, 050104 developmental & child psychology
Abstract

Resume De nombreuses etudes anglo-saxonnes se sont focalisees sur la question des appartenances culturelles et de l’identite culturelle des enfants en situation d’adoption internationale, soulignant la correlation entre identite culturelle positive et forte et meilleur developpement psychologique ulterieur de l’enfant. La notion d’identite culturelle des enfants adoptes est en revanche absente de la litterature francaise. But de l’etude L’objectif de cette etude est de presenter le point de vue des parents adoptants quant aux liens a garder ou non avec le pays de naissance de leur enfant et sa culture. Population et methode Au total, 66 entretiens semi-structures ont ete recueillis aupres de parents ayant adopte dans un autre pays que la France, de facon pleniere. Le guide d’entretien explore le parcours de l’adoption, les liens au pays de naissance de l’enfant, a sa culture, les experiences de racisme. Les entretiens sont analyses selon une methode qualitative, phenomenologique : l’Interpretative Phenomenological Analysis. Resultats Trois grands types de representations parentales des appartenances culturelles de l’enfant sont degages : le premier groupe de parents ne garde aucun lien avec le pays de naissance de leur enfant et refuse la multiplicite des appartenances culturelles de l’enfant. Le deuxieme groupe de parents garde de facon active et reguliere des liens avec le pays de naissance de l’enfant et sa culture et revendique le fait d’etre une famille multiculturelle. Le troisieme groupe de parents adapte les liens au pays de naissance et sa culture en fonction des questionnements et interets de l’enfant. La discussion porte sur ces trois types de strategies parentales, ainsi que leurs implications.

Published
2015

23. Channel characteristics of VDAC-3 from Arabidopsis thaliana

Author

Geneviève Ephritikhine, Rémi Peyronnet, Alexandre Ghazi, Hélène Barbier-Brygoo, Jean-Michel Betton, Jean-Marie Frachisse, Catherine Berrier, Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Microbiologie structurale - Structural Microbiology (Microb. Struc. (UMR_3528 / U-Pasteur_5)), Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), This work was funded by the Centre National de la Recherche Scientifique and by Agence Nationale de la Recherche Grant BLAN06-2-135035, Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Biologie Intégrative de la Cellule ( I2BC ), Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ), Microbiologie structurale, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Institut des Neurosciences de Paris-Saclay (Neuro-PSI), and Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)

Subjects
Gene isoform, MESH : Escherichia coli, Voltage-dependent anion channel, MESH : Recombinant Proteins, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Lipid Bilayers, Biophysics, MESH: Arabidopsis Proteins, Protein Engineering, Biochemistry, MESH : Arabidopsis Proteins, Inclusion bodies, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, MESH: Recombinant Proteins, MESH : Cell-Free System, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Arabidopsis, MESH: Cell-Free System, Escherichia coli, Voltage-Dependent Anion Channels, Arabidopsis thaliana, MESH: Electrophysiological Phenomena, Lipid bilayer, Molecular Biology, Cell-Free System, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, biology, Arabidopsis Proteins, MESH : Voltage-Dependent Anion Channels, MESH: Escherichia coli, MESH: Lipid Bilayers, MESH: Voltage-Dependent Anion Channels, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cell Biology, Protein engineering, Plant cell, biology.organism_classification, Recombinant Proteins, Electrophysiological Phenomena, MESH: Protein Engineering, MESH : Protein Engineering, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH : Electrophysiological Phenomena, biology.protein, MESH : Lipid Bilayers
Abstract

International audience; Four different isoforms of the Voltage-Dependent Anion Channel (VDAC) have been identified in Arabidopsis plant cells. The electrophysiological characteristics of several VDAC channels from animal as well as plant cells are well documented, but those of this model plant are unknown. One isoform, AtVDAC-3 was obtained either directly by cell-free synthesis or produced in Escherichia coli, as inclusion bodies, and re-natured. An electrophysiological study of the purified proteins in planar lipid bilayers showed that both methods yielded proteins with similar channel activity. The characteristics of AtVDAC-3 are that of a bona fide VDAC-like channel.

Published
2015

24. Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental)

Author

Yrondi, Antoine, Bennabi, Djamila, Haffen, Emmanuel, Garnier, Marion, Bellivier, Frank, Bourgerol, Thierry, Camus, Vincent, D'Amato, Thierry, Doumy, Olivier, Haesebaert, Frédéric, Holtzmann, Jérôme, Lançon, Christophe, Vignaud, Philippe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaelle, Domenech, Philippe, Rabu, Corentin, Mallet, Luc, Yon, Liova, Schmitt, Laurent, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Llorca, Pierre-Michel, Courtet, Philippe, Leboyer, Marion, El-Hage, Wissam, Aouizerate, Bruno, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Département de neurosciences (CHU Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor, Oxalya, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service Psychiatrie et psychologie médicale [CHU Purpan], CHU Toulouse [Toulouse], Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Ethique, Professionalisme et Santé (JE 2535-EPS), Université de Brest (UBO)-Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Clermont-Ferrand, Centre Hospitalier Universitaire [Grenoble] (CHU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier le Vinatier [Bron], Hôpital Charles Perrens, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Université Lumière - Lyon 2 (UL2), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Hopital de Bohars - CHRU Brest (CHU - BREST ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Hôpital Henri Mondor, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de psychiatrie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Institut des Sciences Cognitives (ISC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Image, Ville, Environnement (LIVE), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-CHU Clermont-Ferrand, Fondation Fondamental, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre hospitalier Charles Perrens [Bordeaux], Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neurologie et thérapeutique expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), El-Hage, Wissam, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, Département de neurosciences ( CHU Henri Mondor ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Lumière - Lyon 2 ( UL2 ), Laboratoire de Neurosciences de Brest ( LNB ), Université de Brest ( UBO ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Ethique, Professionalisme et Santé ( JE 2535-EPS ), Université de Brest ( UBO ) -Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, CHRU Tours, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, UMR U 1253, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], UMR 7362, Laboratoire Image, Ville, Environnement [Strasbourg] (LIVE), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Douhairie, Marie-Laurence, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), and Guedj, Eric

Subjects
lcsh:RC435-571, assessment, [SDV]Life Sciences [q-bio], [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, depressive disorder, lcsh:Psychiatry, Clinical Study Protocol, ComputingMilieux_MISCELLANEOUS, Psychiatry, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, innovative strategies, [SDV] Life Sciences [q-bio], [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [ SCCO.NEUR ] Cognitive science/Neuroscience, treatment-resistant depression, network, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background Major depression is characterized by (i) a high lifetime prevalence of 16–17% in the general population; (ii) a high frequency of treatment resistance in around 20–30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs. In this context, there is an important need for the development of a network of expert centers for treatment-resistant depression (TRD), as performed under the leadership of the Fondation FondaMental. Methods The principal mission of this national network is to establish a genuine prevention, screening, and diagnosis policy for TRD to offer a systematic, comprehensive, longitudinal, and multidimensional evaluation of cases. A shared electronic medical file is used referring to a common exhaustive and standardized set of assessment tools exploring psychiatric, non-psychiatric, metabolic, biological, and cognitive dimensions of TRD. This is paralleled by a medico-economic evaluation to examine the global economic burden of the disease and related health-care resource utilization. In addition, an integrated biobank has been built by the collection of serum and DNA samples for the measurement of several biomarkers that could further be associated with the treatment resistance in the recruited depressed patients. A French observational long-term follow-up cohort study is currently in progress enabling the extensive assessment of resistant depressed patients. In those unresponsive cases, each expert center proposes relevant therapeutic options that are classically aligned to the international guidelines referring to recognized scientific societies. Discussion This approach is expected to improve the overall clinical assessments and to provide evidence-based information to those clinicians most closely involved in the management of TRD thereby facilitating treatment decisions and choice in everyday clinical practice. This could contribute to significantly improve the poor prognosis, the relapsing course, daily functioning and heavy burden of TRD. Moreover, the newly created French network of expert centers for TRD will be particularly helpful for a better characterization of sociodemographic, clinical, neuropsychological, and biological markers of treatment resistance required for the further development of personalized therapeutic strategies in TRD.

Published
2017

25. Qualité de vie liée à la santé des conjoints de patients âgés souffrant d’un épisode dépressif

Author

Fabien Rondepierre, Candy Auclair, Isabelle Jalenques, Marion Cleret, Barbara Richard, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service d'Addictologie et Pathologie Duelles [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), and Service de Psychiatrie Addictologie, CHU Gabriel Montpied, 63 000 Clermont-Ferrand

Subjects
Gynecology, medicine.medical_specialty, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, General Medicine, 030227 psychiatry, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, medicine, 030212 general & internal medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract

Resume Objectif Evaluer la qualite de vie liee a la sante (QV) des conjoints vivant a domicile avec un patient de 65 ans et plus, souffrant d’un episode depressif caracterise, en comparaison a des temoins apparies et rechercher s’il existe des correlations entre la QV des conjoints et l’evaluation de la depression des patients et des conjoints, ainsi que la charge en soins ressentie par le conjoint. Methodes L’evaluation des patients comportait un diagnostic clinique d’episode depressif caracterise selon le DSM-IV-TR, l’echelle de depression geriatrique GDS-15, l’echelle LEIPAD de QV specifique des sujets âges de 65 ans et plus vivant a domicile. L’evaluation des conjoints comportait la GDS-15, une evaluation du fardeau de l’aidant (echelle Zarit) et la LEIPAD. La QV des temoins a ete evaluee par la LEIPAD ; ceux-ci etaient apparies sur l’âge, le sexe et le niveau d’etudes. Resultats Ont ete incluses 38 personnes : 19 patients âges en moyenne de 76,6 ans (ecart-type 8,1) et leurs conjoints âges de 75,3 ans (ecart-type 8,2). Comparee aux 19 temoins, la QV des conjoints etait significativement degradee pour la dimension « Fonctionnement sexuel » (p = 0,0007) ; la QV des conjoints pour cette dimension etait negativement impactee par la depression des patients (p = 0,02). Les scores de QV des conjoints pour les dimensions « Fonction physique », « Depression et anxiete » et « Fonctionnement sexuel » etaient negativement impactes par la depression des conjoints (coefficient de correlation r = 0,50 ; 0,53 et 0,54 respectivement). La QV des conjoints dans les dimensions « Prendre soin de soi », « Fonctionnement sexuel » et « Satisfaction de vie » etait aussi negativement impactee par la charge en soins ressentie (coefficient de correlation r = 0,59 ; 0,57 et 0,51 respectivement). Conclusion La QV liee a la sante des conjoints âges de patients depressifs caracterises etait significativement degradee pour la dimension liee a la sexualite. Nous avons mis en evidence un impact negatif de la depression des patients, de celle des conjoints et de la charge en soins ressentie par ceux-ci sur plusieurs dimensions de la QV des conjoints. Il semble ainsi important d’evaluer l’etat psychique, la charge en soins et la QV des conjoints aidants de patients âges depressifs, pour proposer si necessaire une aide aux conjoints en difficultes.

Published
2017

26. Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care

Author

Franck Baylé, Laurent Boyer, Arnaud Tessier, Pierre-Michel Llorca, David Misdrahi, Mathilde M. Husky, Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] ( ICMUB ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Hubert Curien [Saint Etienne] ( LHC ), Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre National de la Recherche Scientifique ( CNRS ), THALES Avionics, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire Hubert Curien (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), THALES Avionics Electrical Systems (TAES), and THALES [France]

Subjects
Adult, Male, medicine.medical_specialty, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Medication adherence, Psychological Trauma, Structural equation modeling, Medication Adherence, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Medicine, Humans, In patient, Psychiatry, Biological Psychiatry, ComputingMilieux_MISCELLANEOUS, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Professional-Patient Relations, Awareness, Middle Aged, medicine.disease, Mental health, Non adherence, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Alliance, Multicenter study, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, business, 030217 neurology & neurosurgery, Clinical psychology, Antipsychotic Agents
Abstract

Medication non adherence in schizophrenia is a major cause of relapse and hospitalization and remains for clinicians an important challenge. This study investigates the associations between insight, therapeutic alliance, perceived trauma related to psychiatric treatment and medication adherence in patients with schizophrenia. In this multicenter study, 72 patients were assessed regarding symptomatology, self-reported adherence with medication, insight, medication side-effects, therapeutic alliance and perceived trauma related to psychiatric treatment. Structural Equation Modeling (SEM) was used to test predicted paths among these variables. The data fit a model in which medication adherence was directly predicted by insight, therapeutic alliance and perceived trauma related to psychiatric treatment. Perceived trauma moderates the role of insight on medication adherence. The final model showed good fit, based on four reliable indices. Greater adherence was correlated with higher insight, higher therapeutic alliance and lower perceived trauma. These three variables appear to be important determinants of patient's medication adherence. Medication adherence could be enhanced by reducing perceived trauma and by increasing insight. The need for mental health providers to acknowledge patients' potentially traumatic experience with psychiatric treatment and the need to encourage greater involvement in care are discussed.

Published
2017

27. Rendre dynamique le matériel d'apprentissage du code de la route : un intérêt particulier pour les sourds

Author

Sébastien Laurent, Laurence Paire-Ficout, Stéphane Argon, Jean-Michel Boucheix, Laboratoire Ergonomie et Sciences Cognitives pour les Transports ( IFSTTAR/TS2/LESCOT ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Université de Lyon, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] ( LEAD ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), RP1-J15142 ACOSUR, Cadic, Ifsttar, Laboratoire Ergonomie et Sciences Cognitives pour les Transports (IFSTTAR/TS2/LESCOT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Université de Lyon, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), and Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)

Subjects
CODE DE LA ROUTE, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SPI]Engineering Sciences [physics], [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SPI] Engineering Sciences [physics], [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SPI ] Engineering Sciences [physics], SURDITE, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, ANIMATION 3D
Abstract

Entretiens Jacques Cartier, QUEBEC, CANADA, 16-/10/2017 - 18/10/2017; ACOSUR : Accès au Code de la route et SURdité. Contexte : La réussite à l'examen du code de la route est un facteur facilitant l'insertion sociale et professionnelle. Avec un taux de réussite largement inférieur aux candidats entendants, les individus sourds éprouvent de nombreuses difficultés. Le matériel actuel composé d'images statiques ne serait pas compatible avec des habiletés temporelles dégradées dues à l'absence d'audition. Objectif : La présente étude s'intéresse au bénéfice d'un matériel dynamique basé sur des animations 3D par rapport à un matériel statique dans une tâche de prise de décision. Méthode : 21 candidats sourds et 24 candidats entendants, tous en apprentissage du code de la route, ont participé à l'expérience dans laquelle ils devaient prendre une décision du type « j'y vais, je n'y vais pas » à partir de différentes situations routières. Ces dernières étaient soit dynamiques soit statiques et soient complexes soit simples. Résultats : Les résultats mettent en évidence de meilleures prises de décision avec le matériel animé par rapport au matériel statique, notamment chez les candidats sourds. De plus, l'apport de l'animation s'est révélé d'autant plus efficace que la situation présentée était complexe. Conclusion : Cette étude est la première à mettre en évidence un bénéfice des outils d'apprentissage animés auprès de candidats en difficulté tant au plan linguistique qu'au plan de certaines composantes temporelles. Il est donc primordial de continuer à considérer ces outils comme une solution pertinente à de meilleures conditions d'apprentissage.

Published
2017

28. Acute Neuroinflammation Promotes Cell Responses to 1800 MHz GSM Electromagnetic Fields in the Rat Cerebral Cortex

Author

Julie Lameth, Annie Gervais, Catherine Colin, Philippe Lévêque, Thérèse M. Jay, Jean-Marc Edeline, Michel Mallat, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), BIO-INGENIERIE ( XLIM-BIO-INGENIERIE ), XLIM ( XLIM ), Université de Limoges ( UNILIM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Limoges ( UNILIM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), BIO-INGENIERIE (XLIM-BIO-INGENIERIE), XLIM (XLIM), Université de Limoges (UNILIM)-Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Psychiatrie et Neurosciences (U894), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
0301 basic medicine, Lipopolysaccharides, Male, Neuroimmunomodulation, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Interleukin-1beta, Lipopolysaccharide, Toxicology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Neuroinflammation, Animals, RNA, Messenger, Receptors, AMPA, AMPA receptor, Rats, Wistar, Cerebral Cortex, Inflammation, Neurons, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, General Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Electromagnetic fields, Disease Models, Animal, 030104 developmental biology, Radiofrequency, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Acute Disease, NADPH Oxidase 2, Microglia, Mobile phone, 030217 neurology & neurosurgery, Cell Phone
Abstract

International audience; Mobile phone communications are conveyed by radiofrequency (RF) electromagnetic fields, including pulse-modulated global system for mobile communications (GSM)-1800 MHz, whose effects on the CNS affected by pathological states remain to be specified. Here, we investigated whether a 2-h head-only exposure to GSM-1800 MHz could impact on a neuroinflammatory reaction triggered by lipopolysaccharide (LPS) in 2-week-old or adult rats. We focused on the cerebral cortex in which the specific absorption rate (SAR) of RF averaged 2.9 W/kg. In developing rats, 24 h after GSM exposure, the levels of cortical interleukin-1ß (IL1ß) or NOX2 NADPH oxidase transcripts were reduced by 50 to 60%, in comparison with sham-exposed animals (SAR = 0), as assessed by RT-qPCR. Adult rats exposed to GSM also showed a 50% reduction in the level of IL1ß mRNA, but they differed from developing rats by the lack of NOX2 gene suppression and by displaying a significant growth response of microglial cell processes imaged in anti-Iba1-stained cortical sections. As neuroinflammation is often associated with changes in excitatory neurotransmission, we evaluated changes in expression and phosphorylation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the adult cerebral cortex by Western blot analyses. We found that GSM exposure decreased phosphorylation at two residues on the GluA1 AMPAR subunit (serine 831 and 845). The GSM-induced changes in gene expressions, microglia, and GluA1 phosphorylation did not persist 72 h after RF exposure and were not observed in the absence of LPS pretreatment. Together, our data provide evidence that GSM-1800 MHz can modulate CNS cell responses triggered by an acute neuroinflammatory state.

Published
2017

29. Prise en charge des troubles dépressifs résistants : recommandations françaises formalisées par des experts de l’AFPBN et de la fondation FondaMental

Author

Fanny Moliere, P. Courtet, Bruno Aouizerate, Franck Bellivier, Pierre-Michel Llorca, Isabel Nieto, Emmanuel Haffen, Djamila Bennabi, Wissam El-Hage, Marie-Noëlle Lefebvre, Guillaume Vaiva, Raphaëlle Richieri, Thomas Charpeaud, Florian Stephan, Vincent Camus, Olivier Doumy, Thierry d'Amato, Frédéric Haesebaert, Jean-Baptiste Genty, S. Destouches, Michel Walter, C. Lançon, N. Alaïli, Jérôme Holtzmann, Laurent Schmitt, Antoine Yrondi, Sylvie Lancrenon, Thierry Bougerol, Marion Leboyer, Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ONERA - The French Aerospace Lab [Palaiseau], ONERA-Université Paris Saclay (COmUE), Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire Image, Ville, Environnement [Strasbourg] (LIVE), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Deutsches Elektronen-Synchrotron [Zeuthen] (DESY), Helmholtz-Gemeinschaft = Helmholtz Association, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), ONERA - The French Aerospace Lab ( Palaiseau ), ONERA, Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Laboratoire Image, Ville, Environnement [Strasbourg] ( LIVE ), Université de Strasbourg ( UNISTRA ), Deutsches Elektronen-Synchrotron [Zeuthen] ( DESY ), Helmholtz-Gemeinschaft, Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC ( NEURO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Université de Strasbourg (UNISTRA), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-CHU Clermont-Ferrand

Subjects
medicine.medical_specialty, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Population, Disease, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Indirect costs, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Quality of life (healthcare), Arts and Humanities (miscellaneous), medicine, Psychiatry, education, Depression (differential diagnoses), ComputingMilieux_MISCELLANEOUS, education.field_of_study, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 3. Good health, 030227 psychiatry, Neuropsychopharmacology, Psychiatry and Mental health, Brain stimulation, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Biological psychiatry, business, 030217 neurology & neurosurgery
Abstract

Major depression represents among the most frequent psychiatric disorders in the general population with an estimated lifetime prevalence of 16-17%. It is characterized by high levels of comorbidities with other psychiatric conditions or somatic diseases as well as a recurrent or chronic course in 50 to 80% of the cases leading to negative repercussions on the daily functioning, with an impaired quality of life, and to severe direct/indirect costs. Large cohort studies have supported that failure of a first-line antidepressant treatment is observed in more than 60% of patients. In this case, several treatment strategies have been proposed by classical evidence-based guidelines from internationally recognized scientific societies, referring primarily on: I) the switch to another antidepressant of the same or different class; II) the combination with another antidepressant of complementary pharmacological profile; III) the addition of a wide range of pharmacological agents intending to potentiate the therapeutic effects of the ongoing antidepressant medication; IV) the association with appropriate psychological therapies; and, V) the use of non-invasive brain stimulation techniques. However, although based on the most recently available data and rigorous methodology, standard guidelines have the significant disadvantage of not covering a large variety of clinical conditions, while currently observed in everyday clinical practice. From these considerations, formalized recommendations by a large panel of French experts in the management of depressed patients have been developed under the shared sponsorship of the French Association of Biological Psychiatry and Neuropsychopharmacology (AFPBN) and the Fondation FondaMental. These French recommendations are presented in this special issue in order to provide relevant information about the treatment choices to make, depending particularly on the clinical response to previous treatment lines or the complexity of clinical situations (clinical features, specific populations, psychiatric comorbidities, etc.). Thus, the present approach will be especially helpful for the clinicians enabling to substantially facilitate and guide their clinical decision when confronted to difficult-to-treat forms of major depression in the daily clinical practice. This will be expected to significantly improve the poor prognosis of the treatment-resistant depression thereby lowering the clinical, functional and costly impact owing directly to the disease.

Published
2017

30. Anhedonia is associated with suicidal ideation independently of depression: A meta-analysis

Author

Déborah Dassa, Emilie Olié, Patrizia Zeppegno, Philippe Courtet, Sébastien Guillaume, Déborah Ducasse, Carla Gramaglia, Gwenolé Loas, Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Fondation FondaMental [Créteil], Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Adult, Male, Anhedonia, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Poison control, Suicide prevention, behavioral disciplines and activities, Suicidal Ideation, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, 0302 clinical medicine, Injury prevention, Medicine, Humans, Suicidal ideation, Depression (differential diagnoses), [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, 030227 psychiatry, 3. Good health, meta-analysis, Psychiatry and Mental health, Clinical Psychology, Meta-analysis, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, behavior and behavior mechanisms, Observational study, Female, medicine.symptom, business, 030217 neurology & neurosurgery, psychological phenomena and processes, Clinical psychology
Abstract

International audience; BACKGROUND:Anhedonia is considered a suicide risk factor in patients with major affective disorders. Here, we wanted to quantify the association between anhedonia and current suicidal ideation according to the absence/presence of between-group differences for depressive scores and psychiatric disorders.METHODS:We performed a meta-analysis of data on studies retrieved from Medline, Web of Science, and PsycINFO from 1965 to 2016 using, among others, the terms (suicid* or depression) and anhedonia.RESULTS:We identified 15 observational case-control studies that investigated the anhedonia differences in individuals with and without current (i.e., within the past week, independently of the lifetime suicidality status) suicidal ideation (defined as thoughts of killing oneself). Overall, 657 subjects with and 6,690 subjects without current suicidal ideation could be compared. Anhedonia level was higher in the group with current suicidal ideation than in the group without, with a medium effect size (standardized mean difference = 0.57, z = 5.43, P < 0.001, 95% confidence interval, CI = 0.37-0.79). The association between anhedonia and current suicidal ideation remained significant when controlling for depression and psychiatric disorders. The anhedonia scales used in the selected studies did not allow investigating consummatory and motivational anhedonia separately.CONCLUSION:Our major finding is the robust association between anhedonia and current suicidal ideation, independently of depression. This is highly relevant for the clinicians' daily practice and might help improving suicidal risk detection and the development of new therapeutic strategies for suicide prevention.

Published
2017

31. Native metabotropic glutamate receptor 4 depresses synaptic transmission through an unusual Gαq transduction pathway

Author

Frédéric M. Coquelle, Simon Bossi, Heather McLean, Raoudha Dammak, Marie-Ange Richard, Paulette Decottignies, Christelle Cadilhac, Thomas Bessiron, Solenne Chardonnet, Pierre Le Maréchal, Fabrice Ango, Cathy Isaura Ramos, Hervé Daniel, Céline Boursier, Catherine Berrier, Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), UMS IPSIT, Plate forme d'imagerie cellulaire, Université Paris-Saclay, Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut de Génomique Fonctionnelle - Montpellier GenomiX (IGF MGX), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Génomique Fonctionnelle ( IGF ), Centre National de la Recherche Scientifique ( CNRS ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Montpellier 1 ( UM1 ) -Université de Montpellier ( UM ), Institut de Génomique Fonctionnelle - Montpellier GenomiX ( IGF MGX ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Biologie Intégrative de la Cellule ( I2BC ), Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ), Institut Paris Saclay d’Innovation Thérapeutique (IPSIT), Université Paris-Sud - Paris 11 (UP11)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-BioCampus (BCM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Cerebellum, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Parallel fiber, Neurotransmission, Biology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Cellular and Molecular Neuroscience, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Molecular layer interneurons, Cerebellar cortex, medicine, Synaptic transmission, Pharmacology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Signaling pathway, Metabotropic glutamate receptor 4, Glutamate receptor, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, G protein, Presynaptic metabotropic glutamate receptor 4, 030104 developmental biology, medicine.anatomical_structure, Metabotropic glutamate receptor, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Signal transduction, Neuroscience
Abstract

International audience; In cerebellar cortex, mGlu4 receptors located on parallel fibers play an essential role in normal motor function, but the molecular mechanisms involved are not yet completely understood. Using a strategy combining biochemical and electrophysiological approaches in the rodent cerebellum, we demonstrate that presynaptic mGlu4 receptors control synaptic transmission through an atypical activation of Gαq proteins. First, the Gαq subunit, PLC and PKC signaling proteins present in cerebellar extracts are retained on affinity chromatography columns grafted with different sequences of the cytoplasmic domain of mGlu4 receptor. The i2 loop and the C terminal domain were used as baits, two domains that are known to play a pivotal role in coupling selectivity and efficacy. Second, in situ proximity ligation assays show that native mGlu4 receptors and Gαq subunits are in close physical proximity in cerebellar cortical slices. Finally, electrophysiological experiments demonstrate that the molecular mechanisms underlying mGlu4 receptor-mediated inhibition of transmitter release at cerebellar Parallel Fiber (PF) - Molecular Layer Interneuron (MLI) synapses involves the Gαq-PLC signaling pathway. Taken together, our results provide compelling evidence that, in the rodent cerebellar cortex, mGlu4 receptors act by coupling to the Gαq protein and PLC effector system to reduce glutamate synaptic transmission.

Published
2017

32. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson’s disease

Author

Simon Loiodice, Portia McGhan, Aziz Hafidi, Vitalina Gryshkova, Andre Nogueira da Costa, Renaud Fleurance, David Dardou, Franck Durif, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Développement et Pathologie du Tissu Musculaire (DPTM), Ecole Nationale Vétérinaire de Nantes-Institut National de la Recherche Agronomique (INRA), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Développement et Pathologie du Tissu Musculaire ( DPTM ), Institut National de la Recherche Agronomique ( INRA ) -Ecole Nationale Vétérinaire de Nantes, Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), UCB BioPharma [Braine l’Alleud, Belgium], Centre National de la Recherche Scientifique (CNRS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB), and Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Nantes

Subjects
0301 basic medicine, Male, Parkinson's disease, Pyridines, Dopamine, Receptor, Metabotropic Glutamate 5, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Nucleus Accumbens, Rats, Sprague-Dawley, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Pramipexole, medicine, Animals, Pharmacology (medical), Benzothiazoles, ComputingMilieux_MISCELLANEOUS, Pharmacology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Metabotropic glutamate receptor 5, [SCCO.NEUR]Cognitive science/Neuroscience, Dopaminergic, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Parkinson Disease, medicine.disease, Conditioned place preference, Corpus Striatum, Associative learning, Rats, Up-Regulation, Psychiatry and Mental health, 030104 developmental biology, Receptors, Glutamate, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Impulsive Behavior, [ SCCO.NEUR ] Cognitive science/Neuroscience, alpha-Synuclein, business, Neuroscience, Excitatory Amino Acid Antagonists, 030217 neurology & neurosurgery, medicine.drug, FOSB
Abstract

Impulsive-compulsive disorders in Parkinson’s disease patients have been described as behavioural or substance addictions including pathological gambling or compulsive medication use of dopamine replacement therapy. A substantial gap remains in the understanding of these disorders. We previously demonstrated that the rewarding effect of the D2/D3 agonist pramipexole was enhanced after repeated exposure to L-dopa and alpha-synuclein mediated dopaminergic nigral loss with specific transcriptional signatures suggesting a key involvement of the glutamatergic pathway. Here, we further investigate the therapeutic potential of metabotropic glutamate receptor 5 antagonism in Parkinson’s disease/dopamine replacement therapy related bias of reward-mediated associative learning. We identified protein changes underlying the striatal remodelling associated with the pramipexole-induced conditioned place preference. Acquisition and expression of the pramipexole-induced conditioned place preference were abolished by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-phenylethynyl (pyridine) (conditioned place preference scores obtained with pramipexole conditioning were reduced by 12.5% and 125.8% when 2-methyl-6-phenylethynyl (pyridine) was co-administrated with pramipexole or after the pramipexole conditioning, respectively). Up-regulation of the metabotropic glutamate receptor 5 was found in the dorsomedial-striatum and nucleus accumbens core. Activation of these two brain sub-regions was also highlighted through FosB immunohistochemistry. Convergent molecular and pharmacological data further suggests metabotropic glutamate receptor 5 as a promising therapeutic target for the management of Parkinson’s disease/dopamine replacement therapy related reward bias.

Published
2017

33. Serotonin transporter gene expression predicts the worsening of suicidal ideation and suicide attempts along a long-term follow-up of a Major Depressive Episode

Author

Jorge Lopez-Castroman, Thomas Desmidt, Karine Baumstarck, Pascale Mazzola-Pomietto, Emilie Olié, Philippe Courtet, Julia-Lou Consoloni, Marie-Noëlle Lefebvre, Pierre-Michel Llorca, Mocrane Abbar, El Chérif Ibrahim, Raoul Belzeaux, Jean Naudin, Jean-Michel Azorin, Wissam El-Hage, Xavier Zendjidjian, Emmanuel Haffen, Ludovic Samalin, Fondation FondaMental [Créteil], Neurobiologie des interactions cellulaires et neurophysiopathologie - NICN ( NICN ), Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique ( CNRS ), CIC-CPCET, Hôpital de la Timone [CHU - APHM] ( TIMONE ), Assistance Publique - Hôpitaux de Marseille ( APHM ), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut de Neurosciences de la Timone ( INT ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Service de psychiatrie adulte, Université de Nîmes ( UNIMES ) -Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ) -Hôpital Universitaire Carémeau [Nîmes], Centre Hospitalier Régional Universitaire de Nîmes (.), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Aix Marseille Université ( AMU ), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hôpital Sainte-Marguerite [CHU - APHM] ( Hôpitaux Sud ) -CHU Marseille, Clinique Psychiatrique Universitaire [Tours], CHRU Tours, Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Pôle de Psychiatrie Universitaire Solaris, Marseille, Hôpital Sainte-Marguerite [CHU - APHM] ( Hôpitaux Sud ), Neurobiologie des interactions cellulaires et neurophysiopathologie - NICN (NICN), Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Assistance Publique - Hôpitaux de Marseille (APHM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre National de la Recherche Scientifique (CNRS)-Université de la Méditerranée - Aix-Marseille 2, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Oncology, Male, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Gene Expression, Suicide, Attempted, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Surveys and Questionnaires, Gene expression, Pharmacology (medical), Longitudinal Studies, Prospective cohort study, Major depressive episode, Suicidal ideation, Serotonin transporter, ComputingMilieux_MISCELLANEOUS, Serotonin Plasma Membrane Transport Proteins, biology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Middle Aged, 16. Peace & justice, 3. Good health, Psychiatry and Mental health, Neurology, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Biomarker (medicine), Female, France, medicine.symptom, Adult, medicine.medical_specialty, Peripheral blood mononuclear cell, Polymorphism, Single Nucleotide, Suicidal Ideation, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Internal medicine, medicine, Humans, Genetic Testing, RNA, Messenger, Biological Psychiatry, Pharmacology, Depressive Disorder, Major, Suicide attempt, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, 030227 psychiatry, ROC Curve, Case-Control Studies, biology.protein, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

The quest for biomarkers in suicidal behaviors has been elusive so far, despite their potential utility in clinical practice. One of the most robust biological findings in suicidal behaviors is the alteration of the serotonin transporter function in suicidal individuals. Our main objective was to investigate the predictive value of the serotonin transporter gene expression (SLC6A4) for suicidal ideation and as secondary, for suicide attempts in individuals with a major depressive episode (MDE). A 30-week prospective study was conducted on 148 patients with a MDE and 100 healthy controls including 4 evaluation times (0, 2, 8 and 30 weeks). Blood samples and clinical data were collected and SLC6A4 mRNA levels were measured from peripheral blood mononuclear cells using RT-qPCR. We first demonstrated the stability and reproducibility of SLC6A4 mRNA expression measures over time in healthy controls (F=0.658; p=0.579; η2=0.008; ICC=0.91, 95% CI [0.87-0.94]). Baseline SLC6A4 expression level (OR=0.563 [0.340-0.932], p=0.026) as well as early changes in SLC6A4 expression between baseline and the 2nd week (β=0.200, p=0.042) predicted the worsening of suicidal ideation (WSI) in the following 8 weeks. Moreover, changes in SLC6A4 expression between the 2nd and 8th weeks predicted the occurrence of a suicide attempt within 30 weeks (OR=10.976 [1.438-83.768], p=0.021). Altogether, the baseline level and the changes in SLC6A4 mRNA expression during a MDE might predict the WSI and the occurrence of suicidal attempts and could be a useful biomarker in clinical practice.

Published
2017

34. How Preconceptions About Lung Cancer Treatment Interact With Medical Discourse for Patients Who Accept Chemotherapy?

Author

Pujol , Jean-Louis, Mérel , Jean-Pierre, Roth , Caroline, and Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier )

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, informed consent, oncology, qualitative study, cancer, chemotherapy, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

International audience; OBJECTIVE:Chemotherapy is widely prescribed for lung cancer with palliation as primary end point. This study aimed at determining how preconceptions about lung cancer and its treatment interact with medical discourse into acceptance of chemotherapy.METHODS:Twenty-three purposively selected patients who recently accepted chemotherapy were invited to participate in this survey consisting of semi-structured in-depth interviews. Grounded theory was applied to investigate participants' perceptions of the context that have surrounded their decision to undergo chemotherapy.RESULTS:Major drivers of social representation of illness were linked with stigma. Participants also evoked the disease itself as a stereotype representation of incurable disease. Significant others' experiences were major components of participants' knowledge of chemotherapy. Searching for information regarding lung cancer actively confronted participants with the disease and its prognosis. However, the searching process was self-limited because of the poor prognosis of the disease, insofar as complete information would have precluded from any hope. We therefore identified 3 domains that provide insights into the participant's views and attitude toward chemotherapy: (i) synthesizing preconceptions of disease and chemotherapy with personal medical case; (ii) slowly constructing complex knowledge of cancer and treatment; and (iii) accepting chemotherapy as a surrogate for acknowledging incurable disease.CONCLUSION:Patients have preconceptions about chemotherapy that result from complex features involving social perception, stigma, and significant others' experiences. In this context, developing a personal knowledge about lung cancer and its treatment is a slow construction. This process needs time to be explained and reformulated, so that patients might give their informed consent.

Published
2017

35. High phosphatidylinositol 4-phosphate (PI4P)-dependent ATPase activity for the Drs2p-Cdc50p flippase after removal of its N- and C-terminal extensions

Author

Philippe Champeil, Pierre Le Maréchal, Joseph A. Lyons, Poul Nissen, José Luis Vázquez-Ibar, Cédric Montigny, Aurore Jacquot, Thibaud Dieudonné, Jakob Ulstrup, Miriam-Rose Ash, Guillaume Lenoir, Hassina Azouaoui, Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Nordic-EMBL Partnership for Molecular Medicine, and PUMPkin (DANDRITE), Centre for Membrane Pumps in Cells and Disease (PUMPKIN), Institut de Biologie Intégrative de la Cellule ( I2BC ), Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Nordic-EMBL Partnership for Molecular Medicine, and PUMPkin ( DANDRITE ), and Centre for Membrane Pumps in Cells and Disease ( PUMPKIN )

Subjects
0301 basic medicine, Phosphatidylinositol 4-phosphate, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH : Saccharomyces cerevisiae, Plasma protein binding, Biochemistry, MESH: Thrombin, chemistry.chemical_compound, MESH : Phosphorylation, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Adenosine Triphosphate, MESH: Saccharomyces cerevisiae Proteins, Phosphatidylinositol Phosphates, ATP hydrolysis, MESH : Arginine, lipid-protein interaction, MESH: Adenosine Triphosphate, MESH : Adenosine Triphosphate, Phospholipid Transfer Proteins, Phosphorylation, Phospholipids, MESH : Phospholipid Transfer Proteins, medicine.diagnostic_test, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Hydrolysis, Autophosphorylation, MESH: Phospholipid Transfer Proteins, Thrombin, MESH: Arginine, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, MESH : Protein Binding, Phosphatidylserine, MESH: Phosphatidylinositol Phosphates, MESH: Saccharomyces cerevisiae, phosphoinositide, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, inhibition mechanism, MESH: Protein Domains, autophosphorylation, MESH : Mutation, MESH: Hydrolysis, Protein Binding, CDC50 protein, phosphatidylserine, Saccharomyces cerevisiae Proteins, MESH : Proteolysis, MESH: Mutation, Proteolysis, MESH : Calcium-Transporting ATPases, MESH: Proteolysis, Calcium-Transporting ATPases, Saccharomyces cerevisiae, Biology, Arginine, MESH : Phospholipids, MESH: Calcium-Transporting ATPases, MESH : Saccharomyces cerevisiae Proteins, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Protein Domains, MESH : Hydrolysis, Membrane Biology, medicine, Journal Article, MESH : Phosphatidylinositol Phosphates, MESH: Protein Binding, Phosphatidylinositol, Molecular Biology, MESH: Phospholipids, MESH: Phosphorylation, MESH : Protein Domains, MESH : Thrombin, Cell Biology, Flippase, flippase, 030104 developmental biology, chemistry, Mutation, 030217 neurology & neurosurgery, limited proteolysis
Abstract

International audience; P4-ATPases, also known as phospholipid flippases, are responsible for creating and maintaining transbilayer lipid asymmetry in eukaryotic cell membranes. Here, we use limited proteolysis to investigate the role of the N and C termini in ATP hydrolysis and auto-inhibition of the yeast flippase Drs2p-Cdc50p. We show that limited proteolysis of the detergent-solubilized and purified yeast flippase may result in more than 1 order of magnitude increase of its ATPase activity, which remains dependent on phosphatidylinositol 4-phosphate (PI4P), a regulator of this lipid flippase, and specific to a phosphatidylserine substrate. Using thrombin as the protease, Cdc50p remains intact and in complex with Drs2p, which is cleaved at two positions, namely after Arg104 and after Arg 1290, resulting in a homogeneous sample lacking 104 and 65 residues from its N and C termini, respectively. Removal of the 1291-1302-amino acid region of the C-terminal extension is critical for relieving the auto-inhibition of full-length Drs2p, whereas the 1-104 N-terminal residues have an additional but more modest significance for activity. The present results therefore reveal that trimming off appropriate regions of the terminal extensions of Drs2p can greatly increase its ATPase activity in the presence of PI4P and demonstrate that relief of such auto-inhibition remains compatible with subsequent regulation by PI4P. These experiments suggest that activation of the Drs2p-Cdc50p flippase follows a multistep mechanism, with preliminary release of a number of constraints, possibly through the binding of regulatory proteins in the trans-Golgi network, followed by full activation by PI4P.

Published
2017

36. Coherent Multimodal Sensory Information Allows Switching between Gravitoinertial Contexts

Author

Barbiero , Marie, Rousseau , Célia, Papaxanthis , Charalambos, White , Olivier, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and 'Centre National d'Etudes Spatiales' (CNES) 4800000665 'Institut National de la Sante et de la Recherche Medicale' (INSERM) 'Conseil General de Bourgogne' (France) 'Fonds Europeen de Developpement Regional' (FEDER)

Subjects
internal model, object manipulation, Physiology, switching, grip force, feedback, multisensory information, isometric force production, load force, gravity, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, human centrifuge, precision grip, internal-models, motor control, arm pointing movements, parabolic flight, held objects, reaching movements
Abstract

International audience; Whether the central nervous system is capable to switch between contexts critically depends on experimental details. Motor control studies regularly adopt robotic devices to perturb the dynamics of a certain task. Other approaches investigate motor control by altering the gravitoinertial context itself as in parabolic flights and human centrifuges. In contrast to conventional robotic experiments, where only the hand is perturbed, these gravitoinertial or immersive settings coherently plunge participants into new environments. However, radically different they are, perfect adaptation of motor responses are commonly reported. In object manipulation tasks, this translates into a good matching of the grasping force or grip force to the destabilizing load force. One possible bias in these protocols is the predictability of the forthcoming dynamics. Here we test whether the successful switching and adaptation processes observed in immersive environments are a consequence of the fact that participants can predict the perturbation schedule. We used a short arm human centrifuge to decouple the effects of space and time on the dynamics of an object manipulation task by adding an unnatural explicit position-dependent force. We created different dynamical contexts by asking 20 participants to move the object at three different paces. These contextual sessions were interleaved such that we could simulate concurrent learning. We assessed adaptation by measuring how grip force was adjusted to this unnatural load force. We found that the motor system can switch between new unusual dynamical contexts, as reported by surprisingly well-adjusted grip forces, and that this capacity is not a mere consequence of the ability to predict the time course of the upcoming dynamics. We posit that a coherent flow of multimodal sensory information born in a homogeneous milieu allows switching between dynamical contexts.

Published
2017

37. Genetic Influence on the Sulcal Pits: On the Origin of the First Cortical Folds

Author

Olivier Coulon, Edouard Duchesnay, Jean-François Mangin, Marion Noulhiane, Vincent Frouin, François Leroy, Guillaume Auzias, Yann Le Guen, Ghislaine Dehaene-Lambertz, Unité Analyse et Traitement de l'Information (UNATI), Service NEUROSPIN (NEUROSPIN), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des Sciences de l'Information et des Systèmes (LSIS), Aix Marseille Université (AMU)-Université de Toulon (UTLN)-Arts et Métiers Paristech ENSAM Aix-en-Provence-Centre National de la Recherche Scientifique (CNRS), Neuroimagerie cognitive - Psychologie cognitive expérimentale (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Unité de recherche en NeuroImagerie Applicative Clinique et Translationnelle (UNIACT), ANR-16-CONV-0002,ILCB,ILCB: Institute of Language Communication and the Brain(2016), ANR-11-IDEX-0001,Amidex,INITIATIVE D'EXCELLENCE AIX MARSEILLE UNIVERSITE(2011), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Arts et Métiers Paristech ENSAM Aix-en-Provence-Université de Toulon (UTLN)-Aix Marseille Université (AMU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Saclay (COmUE), CHU Pontchaillou [Rennes], Institut de Neurosciences de la Timone ( INT ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Unité de Recherche Environnement Physique de la plante Horticole ( EPHOR ), Université d'Angers ( UA ) -AGROCAMPUS OUEST, Université Paris Descartes – Institut de psychologie ( UPD5 Psychologie ), Université Paris Descartes - Paris 5 ( UPD5 ), Laboratoire de Recherche BioMédicale ( LBIOM ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Modelling brain structure, function and variability based on high-field MRI data ( PARIETAL ), Service NEUROSPIN ( NEUROSPIN ), Direction de Recherche Fondamentale (CEA) ( DRF (CEA) ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) ( DRF (CEA) ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique ( Inria ) -Institut National de Recherche en Informatique et en Automatique ( Inria ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Laboratoire de Neuroimagerie Assistée par Ordinateur ( LNAO ), Laboratoire des Sciences de l'Information et des Systèmes ( LSIS ), Aix Marseille Université ( AMU ) -Université de Toulon ( UTLN ) -Arts et Métiers Paristech ENSAM Aix-en-Provence-Centre National de la Recherche Scientifique ( CNRS ), Neuroimagerie cognitive (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), ANR-16-CONV-0002,ILCB,Institute of Language Communication and the Brain(2017), and ANR-11-IDEX-0001-02/11-LABX-0036,BLRI,Brain and Language Research Institute(2011)

Subjects
0301 basic medicine, Genotype, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Cognitive Neuroscience, [ SPI.SIGNAL ] Engineering Sciences [physics]/Signal and Image processing, Biology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Genetic variation, Connectome, Humans, Language lateralization, [ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging, ComputingMilieux_MISCELLANEOUS, Cerebral Cortex, Human Connectome Project, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Genetic variants, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Original Articles, Superior temporal sulcus, Heritability, Adult life, 030104 developmental biology, Evolutionary biology, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, 030217 neurology & neurosurgery
Abstract

The influence of genes on cortical structures has been assessed through various phenotypes. The sulcal pits, which are the putative first cortical folds, have for long been assumed to be under tight genetic control, but this was never quantified. We estimated the pit depth heritability in various brain regions using the high quality and large sample size of the Human Connectome Project pedigree cohort. Analysis of additive genetic variance indicated that their heritability ranges between 0.2 and 0.5 and displays a regional genetic control with an overall symmetric pattern between hemispheres. However, a noticeable asymmetry of heritability estimates is observed in the superior temporal sulcus and could thus be related to language lateralization. The heritability range estimated in this study reinforces the idea that cortical shape is determined primarily by nongenetic factors, which is consistent with the important increase of cortical folding from birth to adult life and thus predominantly constrained by environmental factors. Nevertheless, the genetic cues, implicated with various local levels of heritability in the formation of sulcal pits, play a fundamental role in the normal gyral pattern development. Quantifying their influence and identifying the underlying genetic variants would provide insight into neurodevelopmental disorders.

Published
2017

38. Sharing mates and nestboxes is associated with female 'friendship' in European starlings Sturnus vulgaris

Author

Henry , Laurence, Bourguet , Cécile, Coulon , Marion, Heyraud , Christine, Hausberger , Martine, Ethologie animale et humaine (EthoS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche sur les Herbivores - UMR 1213 (UMRH), Institut National de la Recherche Agronomique (INRA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Hungarian Academy of Sciences, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherches sur les Herbivores - UMR 1213 (UMRH), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA), ETHOS, UMR6552, VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut National de la Recherche Agronomique (INRA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Normandie Université (NU)-Normandie Université (NU)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS), Ethologie animale et humaine ( EthoS ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Unité Mixte de Recherches sur les Herbivores ( UMR 1213 Herbivores ), and VetAgro Sup ( VAS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique ( INRA )

Subjects
[ SDV ] Life Sciences [q-bio], [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV]Life Sciences [q-bio], [SCCO.NEUR] Cognitive science/Neuroscience, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV] Life Sciences [q-bio], [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [ SDV.BA.ZV ] Life Sciences [q-bio]/Animal biology/Vertebrate Zoology, [ SCCO.NEUR ] Cognitive science/Neuroscience, [SDV.BA.ZV]Life Sciences [q-bio]/Animal biology/Vertebrate Zoology, [SDV.BA.ZV] Life Sciences [q-bio]/Animal biology/Vertebrate Zoology, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
Abstract

International audience; Breeding decisions in birds involve both mate and nest choice, and there is increasing evidence that social influences may modulate individual choices. Female preferences may be affected by other females’ preferences and mutual choice cannot always be excluded, which makes the whole pattern more complex than assumed by most sexual selection models. Social transmission may be facilitated by particular social bonds, therefore pre-breeding social networks may influence later mate choices. The other case where females share mate or resources is polygyny, generally viewed to only benefit males. If mutual benefits may arise then mechanisms should evolve to reduce the reproductive cost for females such as to reduce the cost of aggression by sharing their mate with a preferred same sex social partner. We tested the hypothesis that females’ mating decisions may be influenced by the pre-breeding social network and that social partner relations established prior to breeding may share decisions (mate/sites) in a facultative polygynous species, the European starling. Two experiments were designed to test the relative importance of male or nest by following the whole dynamics of the breeding cycle from the pre-breeding period until mate and nest selection. In both cases socially isolated females tended to be excluded from breeding, while pre-breeding social partners tended to share mates and to nest in close proximity, mate copying leading in some case to polygyny. The final pattern resulted both from female “likes and dislikes” and male preferences for some females. Aggressive interactions between females were rare. Vocal sharing between females may have been a clue for males as to the degree of social integration of these females.

Published
2017

39. Impact of induced joy on literacy in children: does the nature of the task make a difference?

Author

Frédérique Cuisinier, Francisco Pons, Elise Tornare, Nikolai Olavi Czajkowski, Université Paris Nanterre (UPN), and Université Paris Nanterre ( UPN )

Subjects
Male, media_common.quotation_subject, Emotions, [ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatrics, task complexity, emotion, 050109 social psychology, Experimental and Cognitive Psychology, literacy, 050105 experimental psychology, Developmental psychology, Task (project management), primary school, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Arts and Humanities (miscellaneous), children, Developmental and Educational Psychology, Humans, 0501 psychology and cognitive sciences, Child, Levels-of-processing effect, Function (engineering), media_common, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Grammar, Recall, Induced joy, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 4. Education, 05 social sciences, Linguistics, Cognition, Procedural knowledge, Comprehension, Female, Psychology, Cognitive psychology
Abstract

International audience; This research examined whether induced joy influences fifth graders' performance in literacy tasks. Children were asked to recall a joyful experience, used as a joy induction, before completing either a grammar (Study 1) or textual comprehension task (Study 2). The grammar task involved understanding at the surface level and retrieval of appropriate declarative and procedural knowledge, but limited elaboration unlike the textual comprehension task, which tackled inference generation. By differentiating tasks based on depth of processing required for completion we aimed at testing the validity of two concurrent hypotheses: that of a facilitating effect and that of a detrimental effect of induced joy. Compared to controls, joy induced children showed better performance on the grammar task - specifically children with lower language ability. No differences across groups emerged as a function of joy induction on the text comprehension task. Results are discussed with respect to emotion effects on cognition.

Published
2017

40. Driver's emotional state and vulnerable road user detection

Author

LAFONT , Alex, ROGE , Joceline, Boucheix , Jean-Michel, Laboratoire Ergonomie et Sciences Cognitives pour les Transports (IFSTTAR/TS2/LESCOT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Université de Lyon, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Cadic, Ifsttar, Laboratoire Ergonomie et Sciences Cognitives pour les Transports ( IFSTTAR/TS2/LESCOT ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Université de Lyon, Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] ( LEAD ), and Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
USAGER VULNERABLE, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, COLERE, DRIVING, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, VULNERABLE ROAD USER, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, COUPLED MEASURES, EMOTION, CONDUITE DU VEHICULE, ANGER, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, EMOTIONAL INTENSITY
Abstract

DDI 2017 - 5th International Conference on Driver Distraction and Inattention, PARIS, FRANCE, 20-/03/2017 - 22/03/2017; In 2014, slightly over 3380 deaths occurred on metropolitan French roads (Observatoire National Interministériel de Sécurité Routière [ONISR], 2015). For pedestrians and cyclists the percentage of fatal accidents increased by around 4, and 7% respectively since 2010. In addition, accidents involving pedestrians and cyclists are mostly caused by other road users as motorists, truck or bus drivers making pedestrians and cyclists vulnerable road users [VRU]. Previous investigations showed that VRU visibility for road users (drivers) was a crucial main issue. To address this issue, first of all, attention management to VRU while driving must be investigated. For example, Hole, Tyrrell, and Langham (1996) show that expectations and knowledge about a stimulus would modulate attention to it. However, recent research in the field indicated that driving is also influenced by emotion. Several studies highlighted a specific harmful impact of negative emotions on several processes involved during driving activity (Ellis, and Moore, 1999; Lemercier, and Cellier, 2008), especially for anger (Stephens, and Groeger, 2009; Stephens, Trawley, Madigan and Groeger, 2013) Further, Rogé, El Zufari, Vienne, and Ndiaye (2015) found that a short film which delivered information to car divers about pedestrian, cyclist and motorcyclist vulnerability modified the intensity of negative emotions felt by motorists. In addition, among all emotions experienced during the film viewing, only anger intensity was positively correlated with a change in the visibility distance of VRU (i.e., road distance between a car driver and a VRU when the motorist claimed he has seen him). The greater is the distance, the more visible the VRU is for the driver (Rogé, Douissembekov, and Vienne, 2012). Therefore, in our study, we only wanted to test the role of different anger intensities on VRU detection abilities. For this reason, we chose to set up a VRU detection task on a car driving simulator (in order to avoid real-life risky situations). Anger-elicitation was carried out using short film clips (see Schaefer, Nils, Sanchez, and Philippot, 2010). These films made no reference on driving or road safety and elicited different anger intensities. Film clips were watched by participants before we asked them to complete driving sessions in which they had to detect pedestrians and cyclists. Furthermore, anger can also be characterized by specific physiological patterns that could be recorded (Kreibig, 2010). For these reasons, particular emphasis was placed in our study on emotional assessment in order to get as much feedbacks as possible on individual emotional state during and after driving. Thus, cardiac and ocular measures were recorded during the driving sessions while emotional self-assessments were carried out after each session to know in what extent all measures matched. By this way we were able to explore the relation between experienced emotional intensity and VRU detection abilities. It was also expected to highlight physiological and behavioural patterns linked with different anger intensities attempting at the same time to provide some answers about an optimum anger intensity likely to be beneficial for driving.

Published
2017

41. Hey Teacher, Don’t Leave Them Kids Alone: Action Is Better for Memory than Reading

Author

Béatrice Bourdin, Mathieu Hainselin, Patrick Manolli, Sophie Vankerkore-Candas, Laurence Picard, Centre de Recherche en Psychologie : Cognition, Psychisme et Organisations - UR UPJV 7273 (CRP-CPO), Université de Picardie Jules Verne (UPJV), Laboratoire de Psychologie, Université Bourgogne Franche-Comté [COMUE] (UBFC), Bonus Qualité Recherche (BQR) de l'Université de Picardie Jules Verne, Université de Besançon, CRP-CPO ( EA 7273 ), Université de Picardie Jules Verne ( UPJV ), and Université Bourgogne Franche-Comté ( UBFC )

Subjects
[ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SHS.EDU]Humanities and Social Sciences/Education, lcsh:BF1-990, [SHS.PSY]Humanities and Social Sciences/Psychology, enactment, 050105 experimental psychology, Developmental psychology, Task (project management), [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, memory, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Encoding (memory), Enactment effect, Psychology, 0501 psychology and cognitive sciences, Active listening, Early childhood, Episodic memory, General Psychology, Original Research, education, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 05 social sciences, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cognition, [ SHS.EDU ] Humanities and Social Sciences/Education, teaching, lcsh:Psychology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, action, Childhood memory, 050104 developmental & child psychology
Abstract

International audience; There is no consensus on how the enactment effect (EE), although it is robust, enhances memory. Researchers are currently investigating the cognitive processes underlying this effect, mostly during adulthood; the link between EE and crucial function identified in adulthood such as episodic memory and binding process remains elusive. Therefore, this study aims to verify the existence of EE in 6–10 years old and assess cognitive functions potentially linked to this effect in order to shed light on the mechanisms underlying the EE during childhood. Thirty-five children (15 second graders and 20 fifth graders) were included in this study. They encoded 24 action phrases from a protocol adapted from Hainselin et al. (2014). Encoding occurred under four conditions: Verbal Task, Listening Task, Experimenter-Performed Task, and Subject-Performed Task. Memory performance was assessed for free and cued recall, as well as source memory abilities. ANOVAS were conducted to explore age-related effects on the different scores according to encoding conditions. Correlations between EE scores (Subject-Performed Task/Listening Task) and binding memory scores (short-term binding and episodic memory) were run. Both groups benefited from EE. However, in both groups, performance did not significantly differ between Subject-Performed Task and Experimenter-Performed Task. A positive correlation was found between EE and episodic memory score for second graders and a moderate negative correlation was found between EE and binding scores for fifth graders. Our results confirm the existence of EE in 6 and 10 year olds, but they do not support the multimodal theory (Engelkamp, 2001) or the " glue " theory (Kormi-Nouri and Nilsson, 2001). This suggests instead that episodic memory might not underlie EE during early childhood.

Published
2017
Full Text
View/download PDF

42. Détection précoce des troubles psychiques en milieu scolaire : le dispositif Fil Harmonie

Author

Jean-Pierre Olié, D Monchablon, Marie-Odile Krebs, C Brébant, Raphaël Gaillard, Yannick Morvan, Julie Bourgin, Alice Oppetit, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de physiopathologie des maladies psychiatriques, Université Paris Descartes - Paris 5 (UPD5), Groupement de recherche en Psychiatrie (GDR Psychiatrie (3557)), Centre National de la Recherche Scientifique (CNRS), CHU Sainte Anne, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), Groupement de recherche en Psychiatrie ( GDR Psychiatrie (3557) ), Centre National de la Recherche Scientifique ( CNRS ), Clinique, Psychanalyse, Développement ( CliPsyD ), and Université Paris Nanterre ( UPN )

Subjects
Pediatrics, medicine.medical_specialty, Mixed methods, Prévention, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, Access to care, Détection précoce des troubles psychiatriques, ésSanté scolaire, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 0302 clinical medicine, Arts and Humanities (miscellaneous), Health care, Medicine, Educational health, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Hotline, business.industry, 4. Education, Public health, Early detection, Mental health, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Méthodes mixtes, [SCCO.PSYC]Cognitive science/Psychology, Ligne, Health education, Descriptive research, business, Humanities, 030217 neurology & neurosurgery, Qualitative research, Accès aux soins
Abstract

International audience; RésuméObjectif L'objectif de cette étude est de décrire le fonctionnement du dispositif Fil Harmonie, ligne téléphonique réservée aux professionnels de l'Académie de Paris faisant face à une situation d'un élève en souffrance psychologique ou psychiatrique. Méthodes Il s'agit d'une étude descriptive observationnelle réalisée entre le 18 septembre 2013 et le 12 mai 2014. Les informations transmises lors des 68 appels téléphoniques ont été recueillies, formalisées puis analysées. Nous avons utilisé une méthodologie mixte, associant des analyses de données quantitatives et de données textuelles. Résultats La profession de l'appelant était dans plus de 70 % des cas celle d'infirmière scolaire. L'âge moyen des élèves concernés était de 17,3 ans. Les deux classes les plus représentées étaient la seconde et la classe préparatoire (19,7 % dans les deux cas). Plus de la moitié des jeunes étaient déclarés comme n'ayant jamais eu de prise en charge psychologique antérieure (52,5 %). Les jeunes étaient décrits majoritairement comme isolés socialement (67,2 %), tristes ou anhédoniques (48,2 %). Plus d'un quart (26,7 %) avait déjà redoublé au moins une fois et la majorité (55,9 %) faisait preuve d'absentéisme. L'analyse qualitative a mis en évidence la complexité de la collaboration entre la famille de l'élève et l'établissement scolaire. Conclusion Fil Harmonie propose une nouvelle modalité pour favoriser le dépistage des difficultés psychiques chez les jeunes en milieu scolaire. Ce dispositif aide à la résolution de problème et si nécessaire l'orientation vers des professionnels de santé adéquats grâce à l'intervention d'un professionnel relais. Cette étude de terrain pointe la nécessaire articulation entre professionnels de l'Éducation, professionnels de santé et entourage proche. AbstractObjective Most psychiatric disorders arise during adolescence, a period of life during which school takes an important place. School in France has an official mission of health education and prevention, and early detection of mental disorders is part of these goals. The aim of this study is to describe an innovative service operating in Paris that helps educational staff to deal with students having psychological or psychiatric symptoms. The Fil Harmonie program was launched in 2011. It consists of a telephone line available to all educational staff working for high schools in Paris. Methods When in need of assistance, a member of the educational staff can call the dedicated hotline and expose the situation of their student to a trained psychologist. Over the course of the study, data concerning these phone calls were collected such as: socio-demographic characteristics of the student, the reason behind the call, the caller's professional role within the school, and care pathway information. All data collected during the phone calls were anonymized and computerized. We performed an observational descriptive study based on this data by using mixed methods: we integrated quantitative analysis and qualitative research in order to provide a better understanding of the Fil Harmonie program. Results Between 18 September 2013 and 12 May 2014, the Fil Harmonie program handled 68 calls from educational staff. Students concerned by the calls were aged between 11 and 22 and the average age was 17.3 years. Over half (52.5%) of the pupils concerned had never seen a mental health professional before the call. In more than 70% of cases, the caller was a school nurse while other professionals such as teachers or headmasters represented only a minority of the callers. Approximately two thirds (67.2%) of students were described by the caller as socially isolated and 48.2% were described as sad or anhedonic. One out of four (26.7%) had repeated a school year at least once, and 55.9% of young people for whom a member of staff contacted Fil Harmonie had been missing class. In 56.7% of cases, there had been no contact with the student's family about the psychological situation. The qualitative analysis particularly highlighted the complexity of the collaboration between the family and the educational staff. Conclusion Schooling is an important opportunity to seize in mental health regarding early detection and access to care. By fostering collaboration between educational professionals and mental health services, Fil Harmonie meets a public health objective of prevention and should contribute to the reduction of care delays thus leading to better treatment outcome. Our study shows that such programs are feasible and answer a real need in our current health care system.

Published
2017

43. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study

Author

Franck Baylé, Bernard Vrijens, David Misdrahi, Mathilde M. Husky, Anne-Catherine Lange, Arnaud Tessier, Pierre-Michel Llorca, Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] ( ICMUB ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), AARDEX Group, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), and CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Medication adherence, Medication Adherence, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Dosing, Prospective Studies, Medical prescription, Antipsychotic, Psychiatry, Prospective cohort study, Biological Psychiatry, ComputingMilieux_MISCELLANEOUS, Psychiatric Status Rating Scales, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Gold standard, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Micro-Electrical-Mechanical Systems, Middle Aged, medicine.disease, 3. Good health, 030227 psychiatry, Discontinuation, Psychiatry and Mental health, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Female, Schizophrenic Psychology, Drug Monitoring, business, 030217 neurology & neurosurgery, Antipsychotic Agents
Abstract

Medication Event Monitoring System (MEMS®) is considered the gold standard for the evaluation of medication adherence, yet few studies have applied this method, especially over long periods of time.To investigate medication adherence patterns in a sample of post-discharge patients with schizophrenia monitored with MEMS caps during a six-month period.Adherence to antipsychotics was prospectively investigated using MEMS among 68 patients with schizophrenia. Treatment initiation, implementation or whether or not the patient takes his dosing regimen as prescribed, persistence or the length of time between initiation and discontinuation, and treatment discontinuation were used to describe adherence. Persistence over time was described using Kaplan-Meier curves.After discharge 16% of the patients never initiated treatment. On average 37.3% of patients adhered to treatment in the first 6months. However, a strong decrease in adherence was observed over time (p0.0001), primarily due by treatment non-persistence. Only half of the patients were persistent at 6weeks, persistence further dropped to 19.0% after 6months. Among persistent patients, implementation was consistent over time with 87.8% of patients taking their medication as prescribed on any given day.Dosing profile analysis provides further evidence for the magnitude of non-adherence with antipsychotic prescriptions among post-discharge patients with schizophrenia. Using the high precision of MEMS®, dosing profiles may provide a better understanding of non-adherence patterns and help clinicians determine optimal individualized strategies.

Published
2017

44. Loss-of-function of PTPR γ and ζ, observed in sporadic schizophrenia, causes brain region-specific deregulation of monoamine levels and altered behavior in mice

Author

Thorsten M. Kranz, Jean-Marie Launay, Sheila Harroch, Françoise Lazarini, Véronique Dubreuil, Sylvie Granon, Arnaud Cressant, Jan Sap, Jing Kong, Jacques Callebert, Dolores Malaspina, Institut des Neurosciences Paris-Saclay (NeuroPSI), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Département de Neuroscience - Department of Neuroscience, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), New York University School of Medicine, NYU System (NYU), Génétique Humaine et Fonctions Cognitives, Service de biochimie et biologie moléculaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-IFR139, Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Paris-Saclay ( Neuro-PSI ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre National de la Recherche Scientifique ( CNRS ), Département de Neuroscience, Institut Pasteur [Paris], Department of psychiatry, New York University Langone School of Medicine, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-IFR139, and Université Paris Diderot - Paris 7 ( UPD7 )

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Serotonin, Dopamine, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Hippocampus, Hippocampal formation, Anxiety, Mental disorders, Amygdala, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Mice, 0302 clinical medicine, Contactins, Internal medicine, Phosphatase, medicine, Animals, Social behavior, Prefrontal cortex, Swimming, Pharmacology, Mice, Knockout, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Receptor-Like Protein Tyrosine Phosphatases, Class 5, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, medicine.disease, Corpus Striatum, Aggression, 030104 developmental biology, medicine.anatomical_structure, Endocrinology, Monoamine neurotransmitter, Schizophrenia, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Psychology, 030217 neurology & neurosurgery, Clinical psychology, medicine.drug
Abstract

The receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders. Based on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation. We compared the results with loss-of-function in its close paralogue PTPRZ, previously associated with schizophrenia. We tested PTPRG −/− , PTPRZ −/− , and wild-type male mice for effects on social behavior, forced swim test, and anxiety, as well as on regional brain neurochemistry. The most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia. By contrast, PTPRZ −/− mice demonstrated marked social alteration with increased aggressivity, reminiscent of some positive symptoms of schizophrenia. Both knockouts showed elevated dopamine levels in prefrontal cortex, hippocampus, and most particularly amygdala, but not striatum, accompanied by reduced dopamine beta hydroxylase activity only in amygdala. In addition, PTPRG KO elicited a distinct increase in hippocampal serotonin level not observed in PTPRZ KO. PTPRG and PTPRZ gene loss therefore induces distinct patterns of behavioral change and region-specific alterations in neurotransmitters, highlighting their usefulness as models for neuropsychiatric disorder mechanisms and making these receptors attractive targets for therapy.

Published
2017

45. Cortico-striatal language pathways dynamically adjust for syntactic complexity: A computational study

Author

Krisztina Szalisznyó, David N. Silverstein, Hugues Duffau, Marc Teichmann, Anja Smits, Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] ( IM2A ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Centre de référence sur les démences rares et maladie de Pick, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Service de Neurochirurgie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -CHU Gui de Chauliac [Montpellier], Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs ( INM ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurochirurgie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Neurosciences de Montpellier (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Gui de Chauliac [Montpellier], and Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM)

Subjects
Male, Sentence comprehension, Linguistics and Language, Cognitive Neuroscience, media_common.quotation_subject, Experimental and Cognitive Psychology, computer.software_genre, 050105 experimental psychology, Language and Linguistics, Task (project management), Striatum, Parallel language, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Speech and Hearing, 0302 clinical medicine, Perception, Neural Pathways, Humans, 0501 psychology and cognitive sciences, Cortico-striatal language network, Language, media_common, Reservoir computing, Communication, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Syntax (programming languages), business.industry, 05 social sciences, Linguistics, Corpus Striatum, Frontal Lobe, Semantics, Comprehension, Memory, Short-Term, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Artificial intelligence, business, Psychology, computer, 030217 neurology & neurosurgery, Word (computer architecture), Sentence, Natural language processing
Abstract

International audience; A growing body of literature supports a key role of fronto-striatal circuits in language perception. It is now known that the striatum plays a role in engaging attentional resources and linguistic rule computation while also serving phonological short-term memory capabilities. The ventral semantic and the dorsal phonological stream dichotomy assumed for spoken language processing also seems to play a role in cortico-striatal perception. Based on recent studies that correlate deep Broca-striatal pathways with complex syntax performance, we used a previously developed computational model of frontal-striatal syntax circuits and hypothesized that different parallel language pathways may contribute to canonical and non-canonical sentence comprehension separately. We modified and further analyzed a thematic role assignment task and corresponding reservoir computing model of language circuits, as previously developed by Dominey and coworkers. We examined the models performance under various parameter regimes, by influencing how fast the presented language input decays and altering the temporal dynamics of activated word representations. This enabled us to quantify canonical and non-canonical sentence comprehension abilities. The modeling results suggest that separate cortico-cortical and cortico-striatal circuits may be recruited differently for processing syntactically more difficult and less complicated sentences. Alternatively, a single circuit would need to dynamically and adaptively adjust to syntactic complexity.

Published
2017

46. Attention-Déficit Hyperactivity Disorder Symptoms and Psychological Comorbidity in Eating Disorder Patients

Author

Sala , Loretta, Martinotti , Giovanni, Carenti , ML, Romo , Lucia, Oumaya , M, Pham-Scottez , Alexandra, Rouillon , Frederic, Gorwood , Philip, Janiri , Luigi, Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Hôpital Sainte-Anne, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique des maladies mentales et de l'encéphale ( CMME - Service de psychiatrie ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Sainte-Anne

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.PSYC]Cognitive science/Psychology, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [No keyword], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; [No abstract]

Published
2017

47. La dépression chez les proches de patients souffrant de schizophrénie : effets longitudinaux sur 8 mois du programme ProFamille

Author

E. Valladier, Lucia Romo, Yannick Morvan, Yann Hodé, Dominique Willard, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Centre Hospitalier de Rouffach, Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique, Psychanalyse, Développement ( CliPsyD ), and Université Paris Nanterre ( UPN )

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Depression, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, Intervention, ésPsycho-éducation, 3. Good health, 030227 psychiatry, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 03 medical and health sciences, Psychiatry and Mental health, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 0302 clinical medicine, Arts and Humanities (miscellaneous), [SCCO.PSYC]Cognitive science/Psychology, Schizophrenia, Family, Psychoeducation, Schizophrénie, familiale, 030217 neurology & neurosurgery
Abstract

International audience; IntroductionMental illness such as schizophrenia is a major public health concern. In France, the economic cost of schizophrenia represents 2% of total medical expenditures. Schizophrenia has an impact on health and quality of life not only for patients but also for relatives. Family psychoeducation is a complementary therapeutic intervention to ordinary clinical care deigned to alleviate the burden of care among relatives of patients with schizophrenia. Literature suggests such programs including the patients’ family members reduce the risk of relapse. Current studies also suggest that negative emotions expressed by family members have negative consequences on patients’ mental health and need to be addressed. However, family psychoeducation is still underdeveloped in France. The objective of this study was to assess the longitudinal outcome on depression level of a psychoeducation program for relatives of schizophrenic patients. The program was held in Paris and Région Île-de-France “Cluster ProFramille Île-de-France” between 2012 and 2014.MethodsLevel of participant's depression was assessed by the Center for Epidemiologic Studies – Depression Scale (CES-D). Measures of depression were made for four time points: 2 months before joining the program (T1), at the beginning of the program (T2), at midpoint of the first program module (3 months, T3) and at the end of the first program module (6 months, T4). Repeated-measures ANOVA were performed to assess longitudinal change in a participant's level of depression. Type of coping strategies, knowledge about the disease, dominant thoughts and emotional progress are assessed by the program. Univariate correlation with CES-D differences between T1 and T4 were assessed. Variables with a significant association were included in a multivariate linear model to explain CES-D difference.ResultsSixty-five relatives participated to the “Cluster ProFramille Île-de-France” between 2012 and 2014 and terminated with the first module of the program. Repeated-measures ANOVA on CES-D scores between T1 and T4 (8 months) showed a significant decrease in average scores for all participants. The mean of decrease was 7 points, equivalent to a 26.6% pre-post decrease level of depression. Significant univariate correlations with depression decrease over 8 months were with “psychomotor tiredness”, “frequent worries” and “dealing with worries”. Multivariate linear regression only confirmed the significant role of diminishing fatigue in relation to the decrease of depression.ConclusionOur study's results showed that the ProFamille program was efficient in reducing the level of depression for its participants over an 8 month period. As the participants progressed on managing their fatigue, their depressed moods improved.; IntroductionLa schizophrénie représente un enjeu majeur de santé publique notamment en raison de la charge pesant sur les aidants, les proches et les familles. Les études actuelles montrent que les émotions négatives et notamment le niveau de dépression des membres de la famille auraient un impact négatif sur l’amélioration de l’état de santé psychique de leur proche. Afin de tester l’efficacité du programme psycho-éducatif ProFamille, une évaluation longitudinale a été initiée.MéthodeLe niveau de dépression a été évalué par le Center for Epidemiologic Studies - Depression Scale (CES-D) à quatre reprises : 2 mois avant le début du programme (T1), au début du programme (T2), 3 mois après le début du programme (T3) et à la fin du 1er module du programme soit 6 mois après le début du programme. L’évolution du niveau de dépression a également été mise en relation avec les effets du programme sur les pensées et émotions dominantes, les connaissances et les stratégies de coping des participants.RésultatsLes scores à la CES-D ont diminué de 7 points en moyenne, soit une baisse de 26,6 % à la fin du programme. L’évolution positive des variables « fatigue psychomotrice », « fréquence du souci personnel » et « maîtrise du souci personnel » étaient significativement associées à la diminution du score de CES-D. Seule la variable fatigue restait significativement associée à la diminution du niveau de dépression après ajustement sur les autres variables.ConclusionLe niveau de dépression des participants a diminué significativement au cours du programme et la diminution du niveau de « fatigue psychomotrice » des participants en est le principal contributeur.

Published
2017

48. Construction identitaire à l'adolescence : quelles spécificités dans un contexte d'adoption internationale ?

Author

Mazeaud, Eglantine, Harf, Aurélie, Skandrani, Sara, Taïeb, O., Moro, Marie-Rose, Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Paris-Saclay, Université Paris-Sud - Paris 11 ( UP11 ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Université Paris Descartes - Paris 5 ( UPD5 ), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Université Pierre et Marie Curie - Paris 6 (UPMC), Université Paris-Sud - Paris 11 (UP11), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Descartes - Paris 5 (UPD5), and Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.PSYC]Cognitive science/Psychology, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [No keyword], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; [No abstract]

Published
2017

49. Ettan, le petit accordeur des filiations. OU la nécessité de penser l'altérité en consultation d'adoption internationale

Author

S. Grandclerc, S. Maley Regley, Marie Rose Moro, M. El Husseini, Sara Skandrani, Clinique, Psychanalyse, Développement ( CliPsyD ), Université Paris Nanterre ( UPN ), Laboratoire d'Energétique et de Mécanique Théorique Appliquée ( LEMTA ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Paris-Saclay, Université Paris-Sud - Paris 11 ( UP11 ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Université Paris Descartes - Paris 5 ( UPD5 ), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Maison de Solenn [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Santé mentale et santé publique (SMSP - U1178), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, 05 social sciences, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Psychiatry and Mental health, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 050902 family studies, Pediatrics, Perinatology and Child Health, [SCCO.PSYC]Cognitive science/Psychology, Developmental and Educational Psychology, 0501 psychology and cognitive sciences, [No keyword], 0509 other social sciences, ComputingMilieux_MISCELLANEOUS, 050104 developmental & child psychology
Abstract

Resume A partir de la presentation d’une situation clinique d’adoption, ce travail decrit le fonctionnement d’une consultation groupale d’adoption internationale. Les questionnements qui y sont deposes par une famille sont analyses a plusieurs niveaux : a un niveau collectif, ils interrogent les representations parentales des appartenances culturelles de l’enfant ; a un niveau intersubjectif, ils sont revelateurs de la dynamique familiale et plus particulierement de la problematique de couple ; a un niveau individuel, ils s’inscrivent dans la problematique intrapsychique respective des parents. Ce travail relate ainsi, comment la question de l’alterite de l’enfant, vient se deployer sur plusieurs scenes a la fois. Elle n’est ainsi jamais a comprendre au premier degre, mais necessite de multiples niveaux de lecture, du plus singulier au collectif.

Published
2017

50. Traffic Accidents and Their Recurrenece in at Risk Adolescents and Young Adults : Realities and Perspectives

Author

Gicquel, Ludovic, Ordonneau, P, Blot, E, Romo, Lucia, HAL Nanterre, Administrateur, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique, Psychanalyse, Développement (CliPsyD), Université Paris Nanterre (UPN), Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinique, Psychanalyse, Développement ( CliPsyD ), and Université Paris Nanterre ( UPN )

Subjects
[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PSY] Humanities and Social Sciences/Psychology, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.PSYC]Cognitive science/Psychology, [SCCO.PSYC] Cognitive science/Psychology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, [No keyword], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; [No abstract]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results